[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1616
1. Somerville M, Pitt M: Surveillance of Barrett's oesophagus: do we yet know whether it is worthwhile? Frontline Gastroenterol; 2010 Jul;1(2):88-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surveillance of Barrett's oesophagus: do we yet know whether it is worthwhile?
  • In 2004, the Peninsula Technology Assessment Group developed an economic model to assess the effectiveness and cost effectiveness of surveillance of Barrett's oesophagus in preventing morbidity and mortality from oesophageal adenocarcinoma.
  • While there are now better estimates of some of the model inputs, such as cancer risk and quality of life, the revised values make it less likely that surveillance could prove cost effective.
  • At present, there seems little reason to change our original conclusion that surveillance of Barrett's oesophagus is unlikely to be cost effective and a definitive answer may only be possible from clinical trials now in progress.
  • As newer endoscopic techniques for treating Barrett's oesophagus and adenocarcinoma become more widely used, however, conventional surveillance programmes may no longer be undertaken, and revised economic models will be needed to assess the cost effectiveness of the new clinical pathways.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Gastroenterol Hepatol. 2004 Oct;2(10):868-79 [15476150.001]
  • [Cites] Histopathology. 2009 Jun;54(7):814-9 [19635100.001]
  • [Cites] Endoscopy. 2009 May;41(5):400-8 [19418393.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):501-7 [19410194.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):885-7; author reply 887 [15173278.001]
  • [Cites] Lancet. 2009 Mar 7;373(9666):850-61 [19269522.001]
  • [Cites] Am J Gastroenterol. 2008 Jun;103(6):1340-5 [18510606.001]
  • [Cites] Ann Intern Med. 2003 Feb 4;138(3):176-86 [12558356.001]
  • [Cites] Health Qual Life Outcomes. 2006 Nov 27;4:90 [17129380.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(4):588-99 [18272361.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Jun;7(6):613-23 [19281858.001]
  • [Cites] Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv [16545207.001]
  • [Cites] Am J Epidemiol. 2008 Aug 1;168(3):237-49 [18550563.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2043-53 [10445526.001]
  • [Cites] Pharmacoeconomics. 1998 Apr;13(4):397-409 [10178664.001]
  • [Cites] Am J Gastroenterol. 2008 May;103(5):1079-89 [18445097.001]
  • (PMID = 28839554.001).
  • [ISSN] 2041-4137
  • [Journal-full-title] Frontline gastroenterology
  • [ISO-abbreviation] Frontline Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


2. Spechler SJ, Berta M, Patterson CO: Risk Stratification for Esophageal Adenocarcinoma Screening and Surveillance. Gastroenterol Hepatol (N Y); 2006 Nov;2(11):798-799

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk Stratification for Esophageal Adenocarcinoma Screening and Surveillance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2005 Apr;100(4):927-35 [15784042.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Feb;19 Suppl 1:49-53 [14725579.001]
  • [Cites] Gastrointest Endosc. 2006 Aug;64(2):167-75 [16860063.001]
  • [Cites] Am J Gastroenterol. 2004 Dec;99(12):2295-6 [15571571.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Sep;2(9):744-53 [15354274.001]
  • (PMID = 28381948.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Rastogi A, Sharma P: Short-Segment Barrett's Esophagus and Adenocarcinoma. Gastroenterol Hepatol (N Y); 2006 Feb;2(2):134-139

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-Segment Barrett's Esophagus and Adenocarcinoma.
  • Barrett's esophagus is a known risk factor for the development of adenocarcinoma of the esophagus and esophagogastric junction.
  • Based on the length of the columnar segment at endoscopy, Barrett's esophagus has been arbitrarily separated into two broad categories: long-segment and short-segment.
  • The rapid rise in the incidence of esophageal adenocarcinoma has generated sustained research interest in this lesion.
  • Studies have shown that although the prevalence of short-segment Barrett's esophagus is higher than that of long-segment Barrett's esophagus, the risk of developing dysplasia and adenocarcinoma may actually be lower in those patients with short segment Barrett's esophagus.
  • Nonetheless, both dysplasia and esophageal adenocarcinoma have been reported in patients with short-segment Barrett's esophagus, making this arbitrary distinction clinically unimportant.
  • The current surveillance guidelines remain the same for both short- and long-segment Barrett's esophagus.
  • Another key issue is differentiating short-segment Barrett's esophagus from intestinal metaplasia of the gastric cardia.
  • The latter is distinct from esophageal intestinal metaplasia (ie, Barrett's esophagus) and probably does not warrant surveillance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 1992 Jun;33(6):733-7 [1624150.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Gastroenterology. 1984 Oct;87(4):927-33 [6468881.001]
  • [Cites] Am J Gastroenterol. 1999 Dec;94(12):3413-9 [10606296.001]
  • [Cites] JAMA. 1993 Sep 15;270(11):1320 [8360967.001]
  • [Cites] Gut. 2003 Jan;52(1):24-7 [12477754.001]
  • [Cites] Gastroenterology. 1995 Nov;109(5):1541-6 [7557137.001]
  • [Cites] Am J Gastroenterol. 1997 Mar;92(3):414-8 [9068460.001]
  • [Cites] Dig Dis Sci. 2002 Sep;47(9):2108-11 [12353864.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):277-85 [9922307.001]
  • [Cites] Gastroenterology. 1989 May;96(5 Pt 1):1249-56 [2703113.001]
  • [Cites] Gastrointest Endosc. 2001 May;53(6):559-65 [11323579.001]
  • [Cites] Gastrointest Endosc. 1987 Dec;33(6):413-6 [3443258.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1094-8 [3607726.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1888-95 [12190150.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1670-7 [14724819.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):913-8 [10201456.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1378-82 [11374671.001]
  • [Cites] Gut. 1997 Nov;41(5):585-9 [9414961.001]
  • [Cites] Endoscopy. 1993 Nov;25(9):652-4 [8119225.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1930-6 [12190156.001]
  • [Cites] Ann Intern Med. 2000 Apr 18;132(8):612-20 [10766679.001]
  • [Cites] Dig Dis Sci. 1997 Mar;42(3):597-602 [9073145.001]
  • [Cites] N Engl J Med. 1986 Aug 7;315(6):362-71 [2874485.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] J Gastroenterol. 2004 Jan;39(1):14-20 [14767729.001]
  • [Cites] Ann Surg. 1983 Oct;198(4):554-65 [6625723.001]
  • [Cites] Gut. 1997 Jun;40(6):710-5 [9245922.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):87-94 [11145256.001]
  • [Cites] Lancet. 1994 Dec 3;344(8936):1533-6 [7983953.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Gut. 1996 Jul;39(1):5-8 [8881798.001]
  • [Cites] Am J Gastroenterol. 1996 Aug;91(8):1507-11 [8759651.001]
  • [Cites] Gut. 2000 Jan;46(1):9-13 [10601047.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):942-8 [3402983.001]
  • [Cites] Gastrointest Endosc. 1994 Jan-Feb;40(1):111 [8163114.001]
  • [Cites] Gut. 1998 Jul;43(1):17-21 [9771400.001]
  • [Cites] Gut. 1991 Dec;32(12):1441-6 [1773946.001]
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):289-93 [11522967.001]
  • [Cites] Dig Dis Sci. 1997 Mar;42(3):603-7 [9073146.001]
  • [Cites] Dig Dis Sci. 1992 Jan;37(1):137-43 [1728519.001]
  • [Cites] Br J Surg. 1988 Aug;75(8):760-3 [3167523.001]
  • [Cites] Am J Gastroenterol. 1994 May;89(5):670-80 [8172136.001]
  • [Cites] Gastrointest Endosc. 2005 Feb;61(2):226-31 [15729230.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1155-8 [8339208.001]
  • [Cites] Am J Gastroenterol. 1996 May;91(5):981-6 [8633592.001]
  • [Cites] Am J Gastroenterol. 1997 Nov;92(11):2012-6 [9362182.001]
  • [Cites] Am J Gastroenterol. 1997 Mar;92(3):407-13 [9068459.001]
  • [Cites] Histopathology. 2001 Apr;38(4):307-11 [11318895.001]
  • [Cites] Gut. 1998 May;42(5):659-62 [9659160.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1033-6 [9672325.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1820-8 [8859198.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2037-42 [10445525.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1888-93 [10950031.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):294-301 [11522968.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):937-43 [10201460.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 1985 Oct 3;313(14):857-9 [4033716.001]
  • (PMID = 28286441.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Barrett’s esophagus / adenocarcinoma / high-grade dysplasia / long-segment Barrett’s esophagus / low-grade dysplasia / short-segment Barrett’s esophagus
  •  go-up   go-down


Advertisement
4. Long-term antacid use increases likelihood of oesophageal cancer. Nurs Stand; 2009 Apr 22;23(33):17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term antacid use increases likelihood of oesophageal cancer.
  • : The risk of oesophageal adenocarcinoma is greater in people who take long-term over-the-counter (OTC) acid neutralising drugs when no upper gastrointestinal (GI) condition has been diagnosed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27991114.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Lagarde SM, ten Kate FJ, Richel DJ, Offerhaus GJ, van Lanschot JJ: Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol; 2007 Feb;14(2):977-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction.
  • OBJECTIVE: This review describes genetic and molecular changes related to adenocarcinoma of the esophagus and gastroesophageal junction (GEJ) with emphasis on prognostic value and possibilities for targeted therapy in clinical setting.
  • Adenocarcinoma of the esophagus or GEJ is an aggressive disease with early lymphatic and hematogenous dissemination.
  • Better knowledge of molecular bases may lead to new paradigms, improved prognostication, early diagnosis and individually tailored therapeutic options.
  • METHODS: A review of recent English literature (1990-October 2005) concerning esophageal adenocarcinoma was performed.
  • This review focuses on genetic and molecular changes as prognosticators of adenocarcinoma of the esophagus and GEJ.
  • CONCLUSIONS: Adenocarcinomas of the esophagus and GEJ show multiple genetic alterations, which indicate that progression of cancer is a multistep complex process with many different alterations.
  • Presumably, it is not one molecular factor that can predict the biological behavior of this cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Esophageal Neoplasms / genetics. Esophagogastric Junction


6. Struijs B, de Bree R, van Groeningen CJ, Mooi WJ, Leemans CR: Tonsillar metastasis of oesophageal adenocarcinoma. Eur Arch Otorhinolaryngol; 2008 Jan;265(1):127-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tonsillar metastasis of oesophageal adenocarcinoma.
  • Tonsillar metastasis of adenocarcinoma of the oesophagus has not been reported previously.
  • We report a case of a 57-year-old male with a primary adenocarcinoma of the distal esophagus with a metastasis in the right palatine tonsil.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Tonsillar Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Oral Patol Oral Cir Bucal. 2005 May-Jul;10(3):252-7 [15876970.001]
  • [Cites] World J Surg. 2003 Sep;27(9):1052-7 [12917758.001]
  • [Cites] Z Laryngol Rhinol Otol. 1966 Jun;45(6):389-94 [5985937.001]
  • [Cites] Otolaryngol Clin North Am. 1979 Feb;12(1):29-43 [220581.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1979 Mar-Apr;88(2 Pt 1):235-40 [443718.001]
  • [Cites] Head Neck. 1992 Jan-Feb;14(1):55-7 [1624294.001]
  • [Cites] J Natl Cancer Inst. 1996 Apr 17;88(8):530-5 [8606381.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):328-30 [11373114.001]
  • [Cites] J Laryngol Otol. 1996 Mar;110(3):291-3 [8730375.001]
  • (PMID = 17657505.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2099162
  •  go-up   go-down


7. Chak A, Ochs-Balcom H, Falk G, Grady WM, Kinnard M, Willis JE, Elston R, Eng C: Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev; 2006 Sep;15(9):1668-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction.
  • BACKGROUND AND AIM: The familial aggregation of Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction, jointly termed familial Barrett's esophagus, may represent a complex genetic trait.
  • The aim of this study was to determine the proportion of patients with these diseases who have familial Barrett's esophagus.
  • METHODS: Information on gastroesophageal reflux symptoms, known risk factors for Barrett's esophagus, and family history of Barrett's esophagus and cancers, was collected at six hospitals using a structured questionnaire from probands with either long-segment Barrett's esophagus, adenocarcinoma of the esophagus, or adenocarcinoma of the gastroesophageal junction.
  • Family history of Barrett's esophagus or esophageal cancer in a first- or second-degree relative was determined by reviewing medical records of all relatives reported to be affected.
  • Upon review of medical records of the reportedly affected relatives, familial Barrett's esophagus was definitively determined in the case of 30 (7.3%) probands comprising 17 of 276 (6.2%) with Barrett's esophagus, 11 of 116 (9.5%) with adenocarcinoma of the esophagus, and 2 of 21 (9.5%) with adenocarcinoma of the gastroesophageal junction.
  • The diagnosis in the relative reported by the proband to be affected was found not to be Barrett's esophagus or adenocarcinoma in 15 (3.6%) cases.
  • The diagnosis could not be determined in 26 (6.3%) cases in which the proband reported an affected relative.
  • There were no significant differences in age of disease onset, gender, race, or gastroesophageal reflux symptoms between definitive familial Barrett's esophagus probands and nonfamilial probands.
  • CONCLUSION: Familial Barrett's esophagus can be confirmed in 7.3% of persons presenting with Barrett's esophagus, adenocarcinoma of the esophagus, or adenocarcinoma of the gastroesophageal junction.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Esophageal Neoplasms / genetics. Esophagogastric Junction

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16985029.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA30722; United States / NIDDK NIH HHS / DK / DK002800; United States / NIDDK NIH HHS / DK / DK061426; United States / NIDDK NIH HHS / DK / DK070863; United States / NIGMS NIH HHS / GM / GM28356; United States / PHS HHS / / P30CAD43703; United States / NCI NIH HHS / CA / R25 CA094186
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Reid BJ, Li X, Galipeau PC, Vaughan TL: Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer; 2010 Feb;10(2):87-101
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis.
  • The public health importance of Barrett's oesophagus lies in its association with oesophageal adenocarcinoma.
  • The incidence of oesophageal adenocarcinoma has risen at an alarming rate over the past four decades in many regions of the Western world, and there are indications that the incidence of this disease is on the rise in Asian populations in which it has been rare.
  • Much has been learned of host and environmental risk factors that affect the incidence of oesophageal adenocarcinoma, and data indicate that patients with Barrett's oesophagus rarely develop oesophageal adenocarcinoma.
  • Given that 95% of oesophageal adenocarcinomas arise in individuals without a prior diagnosis of Barrett's oesophagus, what strategies can be used to reduce late diagnosis of oesophageal adenocarcinoma?

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3305-14 [19417022.001]
  • [Cites] N Engl J Med. 2009 May 28;360(22):2277-88 [19474425.001]
  • [Cites] Am J Gastroenterol. 2009 Jun;104(6):1356-62 [19491849.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2079-89 [19567501.001]
  • [Cites] Histopathology. 2009 Jun;54(7):814-9 [19635100.001]
  • [Cites] Am J Gastroenterol. 2009 Sep;104(9):2153-60 [19584833.001]
  • [Cites] BMC Fam Pract. 2009;10:59 [19706198.001]
  • [Cites] Nat Rev Cancer. 2009 Oct;9(10):701-13 [19693097.001]
  • [Cites] Gut. 2009 Nov;58(11):1451-9 [19651633.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Dec;7(12):1299-304 [19523538.001]
  • [Cites] Dis Esophagus. 2009;22(8):676-81 [19222529.001]
  • [Cites] Biomarkers. 2006 Nov-Dec;11(6):547-61 [17056474.001]
  • [Cites] Am J Gastroenterol. 2006 Nov;101(11):2619-28 [16952280.001]
  • [Cites] Gut. 2006 Dec;55(12):1810-20 [17124160.001]
  • [Cites] Semin Radiat Oncol. 2007 Jan;17(1):2-9 [17185192.001]
  • [Cites] Scand J Gastroenterol. 2007 Jan;42(1):23-7 [17190758.001]
  • [Cites] Am J Gastroenterol. 2007 Jan;102(1):10-20 [17266684.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Am J Gastroenterol. 2007 Mar;102(3):483-93; quiz 694 [17338734.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 4;99(7):545-57 [17405999.001]
  • [Cites] World J Gastroenterol. 2007 Mar 14;13(10):1585-94 [17461453.001]
  • [Cites] Cancer Causes Control. 2007 Nov;18(9):1039-46 [17665311.001]
  • [Cites] Cancer Detect Prev. 2007;31(3):233-6 [17646057.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1643-58 [17674367.001]
  • [Cites] Gastrointest Endosc. 2007 Sep;66(3):460-8 [17643436.001]
  • [Cites] Int J Pediatr Obes. 2006;1(2):109-13 [17907323.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2090-6 [17890521.001]
  • [Cites] Am J Gastroenterol. 2007 Nov;102(11):2373-9 [17581270.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Dec;26(11-12):1465-77 [17900269.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Dec;293(6):G1106-13 [17932229.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2637-40 [18086768.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2649-55 [18086770.001]
  • [Cites] Gut. 2008 Feb;57(2):173-80 [17932103.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):174-80 [18386788.001]
  • [Cites] Am J Gastroenterol. 2008 May;103(5):1079-89 [18445097.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1169-78 [18483339.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4163-72 [18519675.001]
  • [Cites] Arch Iran Med. 2008 Jul;11(4):364-70 [18588366.001]
  • [Cites] Gut. 2008 Aug;57(8):1041-8 [18305067.001]
  • [Cites] Am J Epidemiol. 2008 Aug 1;168(3):237-49 [18550563.001]
  • [Cites] J Clin Gastroenterol. 2008 Aug;42(7):806-9 [18385604.001]
  • [Cites] Hum Pathol. 2008 Aug;39(8):1128-35 [18602665.001]
  • [Cites] Jpn J Clin Oncol. 2008 Jul;38(7):464-8 [18664481.001]
  • [Cites] Am J Gastroenterol. 2008 Jul;103(7):1614-23; quiz 1624 [18494834.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7 [18695138.001]
  • [Cites] Genome Res. 2008 Sep;18(9):1518-29 [18577705.001]
  • [Cites] Mutagenesis. 2008 Sep;23(5):399-405 [18515815.001]
  • [Cites] BMC Genomics. 2008;9:394 [18717985.001]
  • [Cites] Gut. 2008 Oct;57(10):1354-9 [18424568.001]
  • [Cites] J Gastrointest Surg. 2008 Oct;12(10):1627-36; discussion 1636-7 [18704598.001]
  • [Cites] Dis Esophagus. 2008;21(6):529-38 [18840137.001]
  • [Cites] Mol Cancer. 2008;7:75 [18831746.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1392-1413, 1413.e1-5 [18801365.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2008 Aug;22(4):659-69 [18971125.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6988-95 [18980994.001]
  • [Cites] Gastrointest Endosc. 2008 Nov;68(5):849-55 [18547567.001]
  • [Cites] Contemp Clin Trials. 2009 Jan;30(1):2-7 [19013259.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Dec;23(12):1785-93 [19120871.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Oct;1(5):308-11 [19138974.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Oct;1(5):329-38 [19138977.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Nov;1(6):413-23 [19138988.001]
  • [Cites] Nat Genet. 2009 Feb;41(2):178-86 [19151715.001]
  • [Cites] Br J Cancer. 2009 Feb 10;100(3):551-7 [19156150.001]
  • [Cites] Am J Clin Nutr. 2009 Mar;89(3):890-6 [19144726.001]
  • [Cites] Cancer Causes Control. 2009 Apr;20(3):279-88 [18839322.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7629-33 [15492292.001]
  • [Cites] Nature. 1975 May 15;255(5505):197-200 [1143315.001]
  • [Cites] J Thorac Cardiovasc Surg. 1975 Nov;70(5):826-35 [1186274.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Gastroenterology. 1989 Feb;96(2 Pt 1):355-67 [2910757.001]
  • [Cites] Stat Med. 1989 Apr;8(4):431-40 [2727467.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Mar;105(3):383-7; discussion 387-8 [8445916.001]
  • [Cites] Stat Med. 1994 May 15;13(9):955-68 [8047747.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Nov;108(5):813-21; discussion 821-2 [7967662.001]
  • [Cites] Cancer Causes Control. 2009 Apr;20(3):303-11 [18853262.001]
  • [Cites] Gastroenterology. 2009 Mar;136(3):799-805 [19162028.001]
  • [Cites] Cell Cycle. 2009 Mar 15;8(6):809-17 [19229128.001]
  • [Cites] Gastroenterology. 2009 Apr;136(4):1215-24, e1-2 [19250648.001]
  • [Cites] Am J Gastroenterol. 2009 Apr;104(4):834-42 [19319131.001]
  • [Cites] Lancet. 2009 Apr 11;373(9671):1301-9 [19328542.001]
  • [Cites] Cancer Biomark. 2009;5(3):143-58 [19407369.001]
  • [Cites] Cancer Prev Res (Phila). 2009 May;2(5):459-65 [19401529.001]
  • [Cites] Histopathology. 2009 May;54(6):699-712 [19438745.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4112-5 [19435894.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):86-91 [9934736.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Gut. 1998 Aug;43(2):216-22 [10189847.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1837-9 [10213488.001]
  • [Cites] Nat Genet. 1999 May;22(1):106-9 [10319873.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):327-35 [10419913.001]
  • [Cites] Br J Surg. 1950 Oct;38(150):175-82 [14791960.001]
  • [Cites] Thorax. 1953 Jun;8(2):87-101 [13077502.001]
  • [Cites] Am J Gastroenterol. 2004 Nov;99(11):2107-14 [15554988.001]
  • [Cites] Semin Cancer Biol. 2005 Feb;15(1):51-60 [15613288.001]
  • [Cites] J Infect Dis. 2005 Mar 1;191(5):761-7 [15688293.001]
  • [Cites] Scand J Gastroenterol. 2004 Dec;39(12):1175-9 [15742992.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):771-8 [15765412.001]
  • [Cites] Am J Gastroenterol. 2005 Apr;100(4):775-83 [15784018.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2478-85 [15814623.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Apr;20(4):633-6 [15836715.001]
  • [Cites] JAMA. 2005 May 4;293(17):2095-101 [15870412.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):285-94 [15947880.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jun;3(6):529-37 [15952094.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Jul;20(7):995-1001 [15955205.001]
  • [Cites] Ann Intern Med. 2005 Aug 2;143(3):199-211 [16061918.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2628-31 [16353151.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Mar 15;23(6):727-33 [16556174.001]
  • [Cites] Gastrointest Endosc. 2006 Apr;63(4):570-80 [16564854.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):468-73 [16565718.001]
  • [Cites] JAMA. 2006 Apr 5;295(13):1549-55 [16595758.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4975-82 [16651456.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):566-72 [16630761.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):872-8 [16702363.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 7;98(11):748-56 [16757699.001]
  • [Cites] J Nutr. 2006 Jul;136(7 Suppl):1935S-1939S [16772463.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3661-97 [16778094.001]
  • [Cites] BMJ. 2006 Jun 24;332(7556):1512 [16793832.001]
  • [Cites] Scand J Gastroenterol. 2006 Aug;41(8):887-91 [16803686.001]
  • [Cites] Cancer Causes Control. 2006 Sep;17(7):901-9 [16841257.001]
  • [Cites] Cancer Causes Control. 2006 Sep;17(7):971-81 [16841264.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1430-6 [16863543.001]
  • [Cites] Aging Cell. 2006 Aug;5(4):325-30 [16913878.001]
  • [Cites] Carcinogenesis. 2006 Sep;27(9):1835-41 [16571649.001]
  • [Cites] Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943 [16928254.001]
  • [Cites] Anal Chem. 2006 Sep 1;78(17):5977-86 [16944874.001]
  • [Cites] Gut. 2006 Oct;55(10):1390-7 [16682429.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1668-73 [16985029.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1935-40 [17035402.001]
  • [Cites] Br J Surg. 2002 Jul;89(7):824-37 [12081731.001]
  • [Cites] Trends Biochem Sci. 2002 Jul;27(7):339-44 [12114022.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):745-52 [12163328.001]
  • [Cites] Gut. 2002 Sep;51(3):323-8 [12171951.001]
  • [Cites] Int J Cancer. 2002 Dec 20;102(6):551-5 [12447994.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):47-56 [12512029.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):98-100 [12672037.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1193-201 [12730860.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2560-6 [12855631.001]
  • [Cites] Lancet. 2005 Aug 20-26;366(9486):662-4 [16112303.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jun;46(6):532-42 [17330261.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1323-8 [17277236.001]
  • [Cites] Mol Cell Proteomics. 2007 Jun;6(6):987-99 [16829691.001]
  • [Cites] Genet Med. 2007 Jun;9(6):341-7 [17575500.001]
  • [Cites] Cancer Causes Control. 2007 Sep;18(7):713-22 [17562192.001]
  • [Cites] Transl Res. 2007 Jul;150(1):3-17 [17585859.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G264-70 [17431220.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):34-41; quiz 311 [17631128.001]
  • [Cites] J Mol Med (Berl). 2007 Jul;85(7):733-43 [17415542.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):403-11 [17681161.001]
  • [Cites] Carcinogenesis. 2005 Sep;26(9):1536-41 [15878910.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2151-6 [16181362.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] Scand J Gastroenterol. 2005 Sep;40(9):1127-8 [16211720.001]
  • [Cites] Gastroenterology. 2005 Oct;129(4):1274-81 [16230080.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):945-52 [16321762.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12):2616-21 [16393209.001]
  • [Cites] J Urol. 2006 Feb;175(2):425-31 [16406965.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Apr;14 Suppl 1:3-9 [10807397.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • [Cites] Am J Gastroenterol. 2000 Oct;95(10):2946-52 [11051373.001]
  • [Cites] Gut. 2001 Mar;48(3):304-9 [11171817.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):322-37 [11224619.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1355-62 [11374668.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1630-9 [11375945.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):721-32 [11562112.001]
  • [Cites] Am J Gastroenterol. 2001 Sep;96(9):2575-83 [11569678.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1055-62 [11588131.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):26-33 [11781277.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):55-9 [11781280.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):633-40 [11874995.001]
  • [Cites] Neoplasia. 2002 Mar-Apr;4(2):121-8 [11896567.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Surg Endosc. 2002 Feb;16(2):263-6 [11967675.001]
  • [Cites] J Gastrointest Surg. 2002 Jan-Feb;6(1):29-35; discussion 36 [11986015.001]
  • [Cites] J Mol Diagn. 2008 Jan;10(1):67-77 [18083688.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):126-34 [18187391.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Feb 15;27(4):316-20 [18062791.001]
  • [Cites] Cell Oncol. 2008;30(1):63-75 [18219111.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1303-10 [18000824.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):352-8 [18268119.001]
  • [Cites] Gut. 2008 Apr;57(4):448-54 [18178609.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):727-31 [18349295.001]
  • [Cites] Gut. 2003 Aug;52(8):1081-4 [12865262.001]
  • [Cites] Gut. 2003 Aug;52(8):1085-9 [12865263.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):940-8 [12942560.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):695-701 [12951588.001]
  • [Cites] J Med Genet. 2003 Sep;40(9):651-6 [12960209.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] Am J Gastroenterol. 2003 Sep;98(9):1931-9 [14499768.001]
  • [Cites] Nature. 2004 Feb 26;427(6977):787 [14985739.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3414-27 [15150093.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):11-6 [15261138.001]
  • [Cites] Br J Surg. 2004 Aug;91(8):997-1003 [15286961.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):579-91 [15286738.001]
  • [Cites] Cancer Causes Control. 2004 Oct;15(8):837-43 [15456997.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Mar;4(2):85-92 [7742727.001]
  • [Cites] Am J Gastroenterol. 1996 Sep;91(9):1855-6 [8792715.001]
  • [Cites] Am J Gastroenterol. 1997 Apr;92(4):586-91 [9128304.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] Gastroenterology. 1997 Nov;113(5):1449-56 [9352846.001]
  • [Cites] Gut. 1997 Sep;41(3):303-7 [9378382.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):588-90 [9485003.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102 [9488582.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1028-32 [9672324.001]
  • (PMID = 20094044.001).
  • [ISSN] 1474-1768
  • [Journal-full-title] Nature reviews. Cancer
  • [ISO-abbreviation] Nat. Rev. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA124911-02; United States / NCI NIH HHS / CA / K05 CA124911; United States / NCI NIH HHS / CA / P01 CA091955; United States / NCI NIH HHS / CA / P01 CA091955-08; United States / NCI NIH HHS / CA / K05 CA124911-02
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 218
  • [Other-IDs] NLM/ NIHMS200752; NLM/ PMC2879265
  •  go-up   go-down


9. Lagarde SM, ten Kate FJ, Reitsma JB, Busch OR, van Lanschot JJ: Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol; 2006 Sep 10;24(26):4347-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction.
  • The incidence of adenocarcinoma of the esophagus is rising rapidly in Western Europe and North America.
  • TNM cancer staging systems predict survival on the basis of the anatomic extent of the tumor.
  • However, the adequacy of the current TNM staging system for adenocarcinoma of the esophagus or gastroesophageal junction (GEJ) is questioned repeatedly.
  • Furthermore, their potential application in the clinical setting in patients with adenocarcinoma of the esophagus or GEJ is discussed.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / therapy. Esophagogastric Junction. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Diagnosis, Computer-Assisted. Humans. Lymphatic Metastasis. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging / methods. Nomograms. Prognosis. Radiotherapy, Adjuvant. Risk Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Mar 1;25(7):907-8; author reply 908-9 [17327616.001]
  • [CommentIn] J Clin Oncol. 2007 Mar 1;25(7):906-7; author reply 908-9 [17327615.001]
  • (PMID = 16963732.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 134
  •  go-up   go-down


10. Bergman JJ: The endoscopic diagnosis and staging of oesophageal adenocarcinoma. Best Pract Res Clin Gastroenterol; 2006;20(5):843-66
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The endoscopic diagnosis and staging of oesophageal adenocarcinoma.
  • The endoscopic evaluation of patients with oesophageal adenocarcinoma does not only serve the purpose of diagnosing the lesion and obtaining biopsies for histological evaluation: a systematic description of advanced lesions is also required to guide further therapeutic decisions.
  • New endoscopic imaging modalities hold the promise of better endoscopic detection of early cancer and its precursor lesions in Barrett's oesophagus.
  • Endoscopic ultrasonography (EUS) is superior to any other imaging modality in the assessment of local tumour infiltration of oesophageal adenocarcinoma and locoregional lymph nodes status.
  • EUS may also play a role in the selection of patients for local endoscopic treatment of early oesophageal cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagoscopy
  • [MeSH-minor] Barrett Esophagus / complications. Barrett Esophagus / diagnosis. Barrett Esophagus / pathology. Barrett Esophagus / therapy. Biopsy, Fine-Needle. Endosonography. Humans. Neoadjuvant Therapy. Neoplasm Staging. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997165.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 70
  •  go-up   go-down


11. Witzig R, Schönberger B, Fink U, Busch R, Gundel H, Sendler A, Peschel C, Siewert JR, Lordick F: Delays in diagnosis and therapy of gastric cancer and esophageal adenocarcinoma. Endoscopy; 2006 Nov;38(11):1122-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delays in diagnosis and therapy of gastric cancer and esophageal adenocarcinoma.
  • BACKGROUND AND STUDY AIMS: In the past, there were long delays in the diagnosis of patients with cancer of the stomach or esophagus.
  • The objective of this study was to describe current delays in the diagnosis and treatment of gastric and esophageal adenocarcinoma and to compare the findings with those from an historical control population treated at the same institutions 10 years earlier.
  • PATIENTS AND METHODS: Patients with biopsy-proven gastric cancer or esophageal adenocarcinoma who were treated at two academic medical centers in Germany between April and October 2003 were consecutively screened for eligibility to take part in the study.
  • RESULTS: The median total delay for patients with gastric cancer (n = 104) was 3.5 months (range 0.3 - 29.6), and in patients with esophageal adenocarcinoma (n = 22) the total delay was significantly shorter (median 2.2 months, range 1.2 - 11.7; P < 0.05).
  • Comparing these findings with those from an historic cohort of patients with gastric cancer (n = 100) revealed a significant decrease in the total delay (3.5 versus 8.0 months, P < 0.001).
  • CONCLUSIONS: The current findings indicate that delays in the diagnosis and treatment of gastric cancer have become significantly shorter within the last 10 years as our understanding of and ability to treat this form of cancer have improved.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / therapy. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy


12. Ladanchuk TC, Johnston BT, Murray LJ, Anderson LA, FINBAR study group: Risk of Barrett's oesophagus, oesophageal adenocarcinoma and reflux oesophagitis and the use of nitrates and asthma medications. Scand J Gastroenterol; 2010 Dec;45(12):1397-403
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of Barrett's oesophagus, oesophageal adenocarcinoma and reflux oesophagitis and the use of nitrates and asthma medications.
  • OBJECTIVE: To investigate the relationship between use of asthma medication and nitrates and risk of reflux oesophagitis, Barrett's oesophagus and oesophageal adenocarcinoma.
  • MATERIAL AND METHODS: Data were collected on use of asthma medication and nitrates at least 1 year before interview from patients with reflux oesophagitis, Barrett's oesophagus and oesophageal adenocarcinoma.
  • Associations between use of asthma medications and nitrates and the risk of reflux oesophagitis, Barrett's oesophagus and oesophageal adenocarcinoma were estimated using multiple logistic regression.
  • RESULTS: Nine hundred and forty-one subjects were recruited: 230 reflux oesophagitis, 224 Barrett's oesophagus, 227 oesophageal adenocarcinoma patients and 260 population controls.
  • Barrett's oesophagus patients were more likely than controls to have had a diagnosis of asthma (odds ratio 2.15, 95% confidence interval 1.15-4.03) and to have used asthma medications (odds ratio 2.13, 95% confidence interval 1.09-4.16).
  • No significant associations were observed between use of asthma medication or nitrates and reflux oesophagitis or oesophageal adenocarcinoma.
  • CONCLUSIONS: Gastro-oesophageal reflux symptoms appear to confound the association between asthma medication use and Barrett's oesophagus.
  • However, it is possible that asthma medications may increase the risk of Barrett's oesophagus by other mechanisms.
  • [MeSH-major] Adenocarcinoma / chemically induced. Anti-Asthmatic Agents / adverse effects. Barrett Esophagus / chemically induced. Esophageal Neoplasms / chemically induced. Esophagitis, Peptic / chemically induced. Nitrates / adverse effects

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20626305.001).
  • [ISSN] 1502-7708
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Asthmatic Agents; 0 / Nitrates
  • [Investigator] Murray LJ; Anderson LA; Johnston BT; Watson RG; McGuigan J; Ferguson HR; Murphy SJ; Reynolds JV; Comber H
  •  go-up   go-down


13. Ilson D, Bains M, Rizk N, Rusch V, Flores R, Park B, Shah M, Kelsen D, Miron B, Goodman K: Phase II trial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin (C), and radiation (RT) in esophageal adenocarcinoma: Preliminary safety analysis. J Clin Oncol; 2009 May 20;27(15_suppl):4573

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin (C), and radiation (RT) in esophageal adenocarcinoma: Preliminary safety analysis.
  • Bev + chemo improves response rate (RR) and time to progression (TTP) when added to weekly I/C in advanced esophagogastric cancer but does not increase chemo toxicity [JCO 24: 5201; 2006].
  • We are now combining in a Phase II trial Bev/I/C with concurrent radiotherapy (RT) in esophageal adenocarcinoma (EA) with the primary endpoint of safety.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963076.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Cheung WY, Zhai R, Kulke M, Heist R, Asomaning K, Ma C, Wang Z, Su L, Christiani D, Liu G: Epidermal growth factor (EGF) gene polymorphism, gastroesophageal reflux disease (GERD), and esophageal adenocarcinoma (EAC) risk. J Clin Oncol; 2009 May 20;27(15_suppl):11029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor (EGF) gene polymorphism, gastroesophageal reflux disease (GERD), and esophageal adenocarcinoma (EAC) risk.
  • : 11029 Background: Single nucleotide polymorphisms (SNPs) of key cancer genes, such as EGF A61G, are associated with an elevated risk of EAC, but the lack of full penetrance indicates that the effects of these SNPs on esophageal carcinogenesis are modified by additional genetic or environmental variables.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963962.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Yoon HH, Powell M, Murphy K, Montgomery EA, Hafez MJ, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Gibson MK, ECOG E1201-T1 Study Group: Outcome prediction based on single nucleotide polymorphisms (SNPs) in DNA repair paths in patients (pts) with esophageal adenocarcinoma (EAC) treated with preoperative (preop) cisplatin (C)-based chemoradiation (CRT): Results from the Eastern Cooperative Oncology Group (ECOG). J Clin Oncol; 2009 May 20;27(15_suppl):4530

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome prediction based on single nucleotide polymorphisms (SNPs) in DNA repair paths in patients (pts) with esophageal adenocarcinoma (EAC) treated with preoperative (preop) cisplatin (C)-based chemoradiation (CRT): Results from the Eastern Cooperative Oncology Group (ECOG).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962996.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Leichman L, Goldman BH, Benedetti JK, Billingsley KG, Thomas CR, Iqbal S, Lenz H, Blanke C, Gold PJ, Corless CL: Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356). J Clin Oncol; 2009 May 20;27(15_suppl):4513

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356).
  • 9 PTS (10%) had in-situ cancer or T1N0M0.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962704.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Kristeleit R, Calvert H, Arkenau H, Olmos D, Adam J, Plummer ER, Lock V, Squires M, Fazal L, Judson I: A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An additional 4 patients received at least six cycles of therapy (squamous cell carcinoma of the lung, adenocarcinoma of the esophagus and colorectal carcinoma [2]) with a best response of stable disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961883.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Capdevila J, Clive S, Tabernero J, Lardelli P, Soto-Matos A, Baselga J, Piera A, Pardos I, Rye R, Smyth JF: Phase I study of the novel anticancer drug PM00104 as a 24-hour IV infusion every 3 weeks (q3w) in patients (pts) with advanced solid tumors or lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):2568

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No objective responses were seen but 3 pts with pancreatic adenocarcinoma, hepatocarcinoma and lower esophagus adenocarcinoma presented stable disease lasting >3 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Rousseau M, Guevremont P, Chasen M, Spicer J, Eckert E, Alcindor T, Ades S, Ferri LE: The management of dysphagia in esophageal cancer patients undergoing neoadjuvant chemotherapy: Is invasive tube feeding required? J Clin Oncol; 2009 May 20;27(15_suppl):9613

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of dysphagia in esophageal cancer patients undergoing neoadjuvant chemotherapy: Is invasive tube feeding required?
  • : 9613 Background: The dysphagia commonly associated with esophageal cancer often interferes with patient tolerance of neo-adjuvant chemotherapy.
  • METHODS: Pts undergoing neoadjuvant chemotherapy (TAX/CDDP/5FU Q3 weeks x3) for esophageal or GEJ adenocarcinoma at a single institution from 3/07-7/08 were identified from a prospective database.
  • CONCLUSIONS: Appropriately timed neoadjuvant chemotherapy with a highly effective regimen rapidly restores normal swallowing, maintains nutritional status, and obviates the need for ITF in patients with significant dysphagia from esophageal adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963863.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Lanas A, Alcedo González J: [Chemoprevention in adenocarcinoma of the esophagus]. Acta Gastroenterol Latinoam; 2007 Mar;37(1):37-48
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemoprevention in adenocarcinoma of the esophagus].
  • [Transliterated title] Quimioprevención en adenocarcinoma de esófago.
  • The incidence of the adenocarcinoma of the esophagus (ACE) has dramatically for the last decades in western countries, which has been associated with a parallel increase in the incidence and prevalence of symptoms associated with gastroesophageal reflux diseases (GERD) and Barrett's esophagus (BE).
  • Different pathways, including overexpression of cyclooxygenase (COX) isoenzymes, has been proposed to explain the carcinogenic process leading from normal esophagus to esophagitis, BE and ACE.
  • The current therapy with protom pump inhibitors (PPI) is effective to reduce the esophageal acid exposure, to improve reflux symptoms, and to heal inflammatory injuries, but probably is not enough to avoid the dysplastic progression of the metaplastic epithelium.
  • [MeSH-major] Adenocarcinoma / prevention & control. Barrett Esophagus / drug therapy. Esophageal Neoplasms / prevention & control. Gastroesophageal Reflux / drug therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17486744.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Argentina
  • [Number-of-references] 93
  •  go-up   go-down


21. Huang Y, Peters CJ, Fitzgerald RC, Gjerset RA: Progressive silencing of p14ARF in oesophageal adenocarcinoma. J Cell Mol Med; 2009 Feb;13(2):398-409
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive silencing of p14ARF in oesophageal adenocarcinoma.
  • The frequency of oesophageal adenocarcinoma is increasing in Western countries for unknown reasons, and correlates with a corresponding increase in the pre-malignant condition, Barrett's Oesophagus, which raises the risk of adenocarcinoma by some 40- to 125-fold.
  • We have examined how disease progression correlates with changes in expression of the p14ARF (ARF) tumour suppressor, a key regulator of the p53 tumour suppressor pathway that is silenced in some 30% of cancers overall, but for which a role in oesophageal cancer is unclear.
  • We have used quantitative PCR, RT-PCR, methylation-specific PCR and chromatin-immunoprecipitation to examine the regulation and function of ARF in oesophageal adenocarcinoma tissue specimens and cell lines.
  • We find highly significant reductions (P< 0.001) in ARF expression during disease progression from normal oesophageal epithelium to Barrett's Oesophagus to adenocarcinoma, with 57/76 (75%) adenocarcinomas displaying undetectable levels of ARF expression.
  • Retention of ARF expression in adenocarcinoma is a highly significant indicator of increased survival (P< 0.001) and outperforms all clinical variables in a multivariate model.
  • CpG methylation as well as histone H3 methylation of lysines 9 and 27 contribute independently to ARF gene silencing in adenocarcinoma cell lines and can be reversed by 5-aza-2'-deoxycytidine.
  • The results suggest that silencing of ARF is involved in the pathogenesis of oesophageal adenocarcinoma and show that either DNA or histone methylation can provide the primary mechanism for ARF gene silencing.
  • [MeSH-major] Adenocarcinoma / genetics. Esophageal Neoplasms / genetics. Gene Silencing. Tumor Suppressor Protein p14ARF
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / metabolism. Azacitidine / analogs & derivatives. Azacitidine / metabolism. Barrett Esophagus / genetics. Barrett Esophagus / pathology. Base Sequence. Cell Line. Disease Progression. Epithelial Cells / cytology. Epithelial Cells / metabolism. Female. Histones / metabolism. Humans. Male. Methylation. Middle Aged. Molecular Sequence Data. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2004 Jun 10;23(27):4780-8 [15107828.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):135-41 [15185075.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6867-73 [15466175.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7629-33 [15492292.001]
  • [Cites] Science. 1994 Apr 15;264(5157):436-40 [8153634.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7081-4 [8692948.001]
  • [Cites] Leukemia. 1997 Jan;11(1):1-5 [9001409.001]
  • [Cites] Br J Cancer. 1997;75(2):258-63 [9010035.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):591-3 [9485004.001]
  • [Cites] Cell. 1998 Mar 20;92(6):713-23 [9529248.001]
  • [Cites] Cell. 1998 Mar 20;92(6):725-34 [9529249.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8292-7 [9653180.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3926-31 [9731504.001]
  • [Cites] Genes Dev. 1998 Oct 1;12(19):2984-91 [9765200.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6457-73 [9774662.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Dis Esophagus. 2006;19(1):10-4 [16364037.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):468-73 [16565718.001]
  • [Cites] Med Sci (Paris). 2006 May;22(5):519-24 [16687121.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5582-91 [16740693.001]
  • [Cites] Int J Biochem Cell Biol. 2006;38(10):1637-41 [16600663.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:129-37 [16869746.001]
  • [Cites] Nat Genet. 2006 Dec;38(12):1386-96 [17099711.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):659-65 [17255290.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):7996-8001 [17804709.001]
  • [Cites] J Nutr. 2007 Dec;137(12):2622-8 [18029474.001]
  • [Cites] Oncogene. 1999 Oct 21;18(43):5843-9 [10557071.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):129-33 [10646864.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3153-8 [10955797.001]
  • [Cites] Genes Dev. 2000 Sep 15;14(18):2358-65 [10995391.001]
  • [Cites] Carcinogenesis. 2000 Nov;21(11):2057-64 [11062168.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2816-21 [11306450.001]
  • [Cites] Oral Oncol. 2001 Jun;37(4):341-4 [11337265.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):5025-32 [11526487.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 9;288(4):921-6 [11688997.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8284-9 [11719461.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3071-83 [11721752.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Virchows Arch. 2002 Aug;441(2):133-42 [12189502.001]
  • [Cites] Cancer Gene Ther. 2002 Oct;9(10):830-9 [12224024.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6456-61 [12438235.001]
  • [Cites] Pathol Res Pract. 2002;198(12):785-94 [12608655.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):98-100 [12672037.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Jun;18(6):683-9 [12753151.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4211-7 [12874028.001]
  • (PMID = 18410530.001).
  • [ISSN] 1582-4934
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA111868-02; United States / NCI NIH HHS / CA / R01 CA111868-03; United Kingdom / Medical Research Council / / MC/ U105365007; United States / NCI NIH HHS / CA / R01 CA111868-01; United States / NCI NIH HHS / CA / CA 111868; United Kingdom / Medical Research Council / / ; United States / NCI NIH HHS / CA / R01 CA111868-04; United States / NCI NIH HHS / CA / R01 CA111868-05; United States / NCI NIH HHS / CA / R01 CA111868; United States / NCI NIH HHS / CA / R01 CA111868-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Histones; 0 / Tumor Suppressor Protein p14ARF; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ NIHMS289834; NLM/ PMC3098888
  •  go-up   go-down


22. Leers J, Bollschweiler E, Hölscher AH: [Symptoms in patients with adenocarcinoma of the esophagus]. Z Gastroenterol; 2005 Mar;43(3):275-80
MedlinePlus Health Information. consumer health - GERD.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Symptoms in patients with adenocarcinoma of the esophagus].
  • [Transliterated title] Refluxanamnese von Patienten mit Adenokarzinom der Speiseröhre.
  • INTRODUCTION: Gastroesophageal reflux (GER) is the main risk factor for the development of adenocarcinoma of the esophagus (AC).
  • In 21 % of the patients the reflux symptoms stopped (median) three years (range two months -- 30 years) before the diagnosis of the carcinoma.
  • Only 55 % of all patients had one or more esophago-gastroscopy examinations before the diagnosis of AC.
  • These patients showed significantly more often earlier tumour stages than those patients without an endoscopy before diagnosis.
  • CONCLUSIONS: 15 % of the patients with adenocarcinoma of the esophagus show no, and in addition 25 % only discrete, heartburn; 1. an endoscopy due to heartburn was done in half of all cases, and 2. the medications do not fulfil the therapeutic standard; 3.patients with endoscopy had significantly more frequently an earlier tumour stage.
  • [MeSH-major] Adenocarcinoma / diagnosis. Esophageal Neoplasms / diagnosis. Gastroesophageal Reflux / complications
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alcohol Drinking. Barrett Esophagus / complications. Body Mass Index. Chi-Square Distribution. Confidence Intervals. Esophagectomy. Esophagoscopy. Female. Gastroscopy. Humans. Male. Middle Aged. Occupations. Prospective Studies. Risk Factors. Smoking / adverse effects. Surveys and Questionnaires. Time Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15765300.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Haghdoost AA, Hosseini H, Chamani G, Zarei MR, Rad M, Hashemipoor M, Zahedi MJ, Darvish-Moghadam S: Rising incidence of adenocarcinoma of the esophagus in Kerman, Iran. Arch Iran Med; 2008 Jul;11(4):364-70
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rising incidence of adenocarcinoma of the esophagus in Kerman, Iran.
  • BACKGROUND: The fall in the incidence of esophageal squamous cell cancer and noncardia gastric cancers in western countries parallels a concomitant rise in the incidence of gastric cardia cancer and distal adenocarcinoma of the esophagus.
  • We aimed to investigate the incidence trend of different gastric and esophageal cancers in Kerman, southeast Iran.
  • METHODS: The information of all newly diagnosed patients with gastric and esophageal cancers were collected actively from all histopathology departments around the Kerman Province during 1991 - 2002 retrospectively.
  • RESULTS: The annual age standardized incidence risks of esophageal and gastric cancers in Kerman were 1.9 and 6.9 per 100,000 populations.
  • In average, the risks of gastric and esophageal squamous cell cancers were more or less constant, while the risk of adenocarcinoma of the esophagus increased around 11% annually.
  • The rising incidence of adenocarcinoma of the esophagus in Kerman parallels its temporal pattern in western countries.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18588366.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Iran
  •  go-up   go-down


24. Gillen S, Feith M, Gertler R, Langer R, Massmann J, Sarbia M, Friess H: Testicular metastasis from adenocarcinoma of the esophagus. Ann Thorac Surg; 2009 Mar;87(3):957-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular metastasis from adenocarcinoma of the esophagus.
  • We report the case of a 61-year-old patient, operated on for adenocarcinoma of the esophagus in 2002, who presented in 2007 with a hydrocele and palpable mass of the right testis.
  • Histopathology revealed a testicular and epididymidal metastasis from the esophageal adenocarcinoma.
  • No case of testicular metastasis from esophageal cancer, including Barrett's carcinoma has been reported.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Testicular Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19231438.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


25. Paterson AL, Fitzgerald RC: Biomarkers in Barrett's oesophagus and oesophageal adenocarcinoma. Expert Opin Med Diagn; 2007 Nov;1(3):363-76

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarkers in Barrett's oesophagus and oesophageal adenocarcinoma.
  • Barrett's oesophagus is a well-recognised premalignant lesion for oesophageal adenocarcinoma.
  • It is present in 1 - 2% of the general population, and 2 - 5% of those with gastro-oesophageal reflux disease.
  • The majority of Barrett's cases within the population are undiagnosed, consequently most cases of oesophageal adenocarcinoma arise de novo.
  • The incidence of oesophageal adenocarcinoma has increased by more than sixfold in the last 30 years.
  • However, most patients with Barrett's oesophagus will not develop oesophageal adenocarcinoma.
  • The major focus of biomarker research in Barrett's oesophagus is to find a marker that is able to identify patients at the highest risk of progressing to adenocarcinoma.
  • Other potential roles include increasing the sensitivity of minimally invasive screening tests to identify patients with Barrett's oesophagus and predicting which patients are most likely to benefit from chemoprevention and endoscopic therapies.
  • In established oesophageal adenocarcinoma, biomarkers would be able to individualise patient management by providing valuable information on patient prognosis and their suitability for novel targeted therapies.
  • This review aims to explore the potential roles of biomarkers in Barrett's oesophagus and oesophageal adenocarcinoma, focusing on the most extensively studied candidates and future novel developments.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23489356.001).
  • [ISSN] 1753-0059
  • [Journal-full-title] Expert opinion on medical diagnostics
  • [ISO-abbreviation] Expert Opin Med Diagn
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Lagergren J: Controversies surrounding body mass, reflux, and risk of oesophageal adenocarcinoma. Lancet Oncol; 2006 Apr;7(4):347-9
MedlinePlus Health Information. consumer health - GERD.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversies surrounding body mass, reflux, and risk of oesophageal adenocarcinoma.
  • At first the association between body mass, reflux, and oesophageal adenocarcinoma might seem easily interpreted, but a more thorough assessment of the published work shows that several factors are missing.
  • Reflux and obesity are established risk factors for oesophageal adenocarcinoma, particularly when they occur in combination.
  • However, the interplay between these and other factors with regard to oesophageal adenocarcinoma is uncertain.
  • Moreover, the contribution of these risk factors in explaining the increasing incidence of oesophageal adenocarcinoma is unclear, because the trends in prevalence of reflux and obesity do not match those of incidence of oesophageal adenocarcinoma.
  • Moreover, none of these factors contribute strongly to the striking predominance of oesophageal adenocarcinoma in men.
  • Thus, several factors that can explain the development of oesophageal adenocarcinoma need to be addressed.
  • [MeSH-major] Adenocarcinoma / etiology. Body Mass Index. Esophageal Neoplasms / etiology. Gastroesophageal Reflux / complications. Gastroesophageal Reflux / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16574550.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


27. Vial M, Grande L, Pera M: Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res; 2010;182:1-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third.
  • The incidence of adenocarcinoma of the esophagus and esophagogastric junction (gastric cardia) has risen rapidly over the past three decades in the United States and northern Europe.
  • The majority of these cancers arise from Barrett's esophagus.
  • However, less than 10% of the patients with esophageal adenocarcinoma were known to have Barrett's esophagus before.
  • Current evidence indicates that gastroesophageal reflux and obesity are major risk factors for adenocarcinoma of the esophagus.
  • Abdominal obesity, more prevalent in males, and independent of body mass index, seems to be associated with an increased risk of esophageal adenocarcinoma but not of cardia adenocarcinoma.
  • This observation may explain the high male:female ratio observed in esophageal adenocarcinoma.
  • Tobacco use has also been found as a possible risk factor for adenocarcinoma of the esophagus and gastric cardia.
  • On the other hand, low intake of fruits, vegetables, and cereal fibers seem to increase the risk of esophageal adenocarcinoma.
  • Currently, there is no evidence that strongly supports any specific strategy to screen a subgroup of the population at risk for adenocarcinoma of the esophagus or esophagogastric junction.
  • Future strategies to decrease obesity and tobacco use might help to reduce the burden of esophageal adenocarcinoma at least partially.
  • [MeSH-major] Adenocarcinoma / epidemiology. Cardia. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology
  • [MeSH-minor] Barrett Esophagus / complications. Esophagogastric Junction. Female. Gastroesophageal Reflux / complications. Helicobacter Infections / complications. Helicobacter pylori. Humans. Male. Obesity / complications

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676867.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


28. Westerterp M, Sloof GW, Hoekstra OS, Ten Kate FJ, Meijer GA, Reitsma JB, Boellaard R, van Lanschot JJ, Molthoff CF: 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol; 2008 Feb;134(2):227-36
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome.
  • PURPOSE: Variable uptake of 18FDG has been noticed in positron emission tomography (PET) studies of patients with oesophageal adenocarcinoma.
  • The aim of the present study was to investigate biological parameters involved in 18FDG uptake in oesophageal adenocarcinoma for selection of patients with increased 18FDG uptake and prediction of prognostic value of 18FDG PET.
  • PATIENTS AND METHODS: Preoperative PET scans were performed in 26 patients with histologically proven oesophageal adenocarcinoma.
  • CONCLUSIONS: Glut-1 expression and tumour size seem parameters associated with 18FDG uptake in patients with biopsy proven oesophageal adenocarcinoma, and may be used to select oesophageal cancer patients in whom 18FDG-PET is of diagnostic value and may predict disease outcome.
  • [MeSH-major] Adenocarcinoma / metabolism. Esophageal Neoplasms / metabolism. Fluorodeoxyglucose F18 / pharmacokinetics. Radiopharmaceuticals / pharmacokinetics
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Esophagectomy. Esophagogastric Junction / diagnostic imaging. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Positron-Emission Tomography. Preoperative Care. Tissue Array Analysis. Tissue Distribution. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med. 2001 Dec;28(12 ):1845-9 [11734925.001]
  • [Cites] Eur J Nucl Med. 1999 Jun;26(6):599-605 [10369945.001]
  • [Cites] Anticancer Res. 2003 Jul-Aug;23 (4):3263-72 [12926062.001]
  • [Cites] J Nucl Med. 2004 Sep;45(9):1519-27 [15347719.001]
  • [Cites] Langenbecks Arch Surg. 2004 Aug;389(4):283-8 [15197549.001]
  • [Cites] AJR Am J Roentgenol. 2005 Aug;185(2):436-40 [16037517.001]
  • [Cites] Cancer. 1998 Sep 1;83(5):918-24 [9731895.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Jul 16;170(1):223-30 [2372287.001]
  • [Cites] J Nucl Med. 2001 Jan;42(1):9-16 [11197987.001]
  • [Cites] J Nucl Med. 2004 Jun;45(6):930-2 [15181126.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3805-12 [15365078.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3202-10 [10986052.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Dec;130(12 ):1361-7 [15611393.001]
  • [Cites] J Nucl Med. 1991 Aug;32(8):1508-12 [1869970.001]
  • [Cites] Clin Radiol. 1998 Sep;53(9):659-65 [9766719.001]
  • [Cites] J Bone Joint Surg Am. 2004 Dec;86-A(12 ):2677-85 [15590853.001]
  • [Cites] J Gastrointest Surg. 2005 Jan;9(1):54-61 [15623445.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):286-94 [15650639.001]
  • [Cites] Nuklearmedizin. 2003 Jun;42(3):90-3 [12802470.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4692-8 [16966684.001]
  • [Cites] Neurology. 1982 Dec;32(12 ):1323-9 [6983044.001]
  • [Cites] Cancer. 1988 May 1;61(9):1776-81 [3355975.001]
  • [Cites] Ann Thorac Surg. 2006 Aug;82(2):391-4; discussion 394-5 [16863735.001]
  • [Cites] Ann Thorac Surg. 1999 Oct;68(4):1133-6; discussion 1136-7 [10543468.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2227-34 [9610703.001]
  • [Cites] Am J Physiol. 1980 Jan;238(1):E69-82 [6965568.001]
  • [Cites] J Cell Physiol. 2005 Mar;202(3):654-62 [15389572.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):224-9 [14710233.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):294-301 [15791438.001]
  • [Cites] J Biol Chem. 1997 Sep 5;272(36):22776-80 [9278438.001]
  • [Cites] Eur J Nucl Med. 2000 Dec;27(12):1778-85 [24578007.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S80-7 [15127240.001]
  • [Cites] J Nucl Med. 2002 Jan;43(1):39-45 [11801701.001]
  • [Cites] Ann Thorac Surg. 2006 Mar;81(3):1076-81 [16488726.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4709-14 [10493529.001]
  • [Cites] J Surg Oncol. 2004 Aug 1;87(2):95-104 [15282704.001]
  • [Cites] Eur J Nucl Med. 2001 Nov;28(11):1690-6 [11702112.001]
  • [Cites] J Nucl Med. 2004 Oct;45(10 ):1632-9 [15471826.001]
  • [Cites] J Nucl Med. 2004 Nov;45(11):1843-50 [15534053.001]
  • [Cites] J Nucl Med. 1996 Jun;37(6):1042-7 [8683298.001]
  • [Cites] Hepatogastroenterology. 2005 Mar-Apr;52(62):486-90 [15816463.001]
  • [Cites] J Clin Oncol. 1999 Oct;17 (10 ):3201-6 [10506619.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):328-34 [15509640.001]
  • [Cites] Radiology. 2003 Jun;227(3):764-70 [12773680.001]
  • [Cites] Br J Cancer. 2002 May 6;86(9):1391-5 [11986769.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):379-87 [11786564.001]
  • [Cites] Eur J Nucl Med. 1998 Oct;25(10 ):1429-34 [9818284.001]
  • [Cites] J Nucl Med. 1995 Oct;36(10 ):1836-9 [7562051.001]
  • [Cites] J Nucl Med. 2002 Feb;43(2):173-80 [11850481.001]
  • [Cites] J Nucl Med. 1993 Mar;34(3):414-9 [8441032.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3315-23 [12429617.001]
  • [Cites] Clin Nucl Med. 2000 Nov;25(11):882-7 [11079584.001]
  • [Cites] Biol Res. 2002;35(1):9-26 [12125211.001]
  • [Cites] Br J Biomed Sci. 2000;57(2):170-8 [10912295.001]
  • [Cites] J Nucl Med. 1997 Oct;38(10 ):1614-23 [9379202.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Oct;18(4):425-8 [11024379.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Mar;34(3):392-404 [17033848.001]
  • [Cites] Surg Oncol. 2001 Nov;10(3):81-90 [11750227.001]
  • (PMID = 17653575.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


29. Wijnhoven BP, Hussey DJ, Watson DI, Tsykin A, Smith CM, Michael MZ, South Australian Oesophageal Research Group: MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br J Surg; 2010 Jun;97(6):853-61
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma.
  • BACKGROUND: The genetic changes that drive metaplastic progression from squamous oesophageal mucosa toward intestinal metaplasia and adenocarcinoma are unclear.
  • The aberrant expression of microRNAs (miRNAs) is involved in the development of cancer.
  • This study examined whether miRNAs play a role in the development of oesophageal adenocarcinoma.
  • METHODS: RNA was extracted from mucosa of normal oesophageal squamous epithelium, normal gastric epithelium, Barrett's oesophagus with intestinal metaplasia and oesophageal adenocarcinoma obtained from 16 individuals.
  • Expression of miR-143, miR-145 and miR-215 was lower in oesophageal adenocarcinoma than in Barrett's oesophagus.
  • MiR-205 levels were lower in gastric epithelium than in both Barrett's oesophagus and adenocarcinoma.
  • CONCLUSION: Expression of miRNA might define disease states in oesophageal epithelium.
  • Dysregulation of specific miRNAs could contribute to metaplastic and neoplastic processes in the oesophageal mucosa.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Esophageal Neoplasms / genetics. MicroRNAs / analysis. RNA, Messenger / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20301167.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Messenger
  • [Investigator] Wijnhoven BP; Hussey DJ; Watson DI; Smith CM; Mayne GC; Michael MZ; Astill D; Van der Hoek MB; Tsykin A; Tilanus HW; Wijnhoven BP
  •  go-up   go-down


30. Desai HG, Kamani PM: Factors responsible for the increasing incidence of oesophageal adenocarcinoma. J Assoc Physicians India; 2007 Jun;55:435-7
MedlinePlus Health Information. consumer health - International Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors responsible for the increasing incidence of oesophageal adenocarcinoma.
  • Amongst white population of developed countries, the prevalence of oesophageal adenocarcinoma has dramatically increased during the last four decades.
  • During this period, the increased damage to the oesophageal mucosa with gastroesophageal reflux could result from increased acid output (due to absence of Helicobacter pylori in the gastric mucosa with excellent sanitation) and/or increased frequency of reflux due to an "epidemic" of overweight (65% of the population).
  • The most important environmental factors, responsible for the fastest increasing cancer in humans, are discussed.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / epidemiology. Global Health. Helicobacter Infections / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879499.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 51
  •  go-up   go-down


31. Chak A, Faulx A, Eng C, Grady W, Kinnard M, Ochs-Balcom H, Falk G: Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia. Cancer; 2006 Nov 1;107(9):2160-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia.
  • BACKGROUND: The efficacy of endoscopic screening for chronic gastroesophageal reflux symptoms of heartburn and regurgitation in adult subjects depends on the sensitivity of this strategy for detecting Barrett esophagus in subjects before the development of adenocarcinoma of the esophagus or cardia.
  • The aim of the current study was to determine what proportion of patients with cancer of the esophagus or cardia would have been candidates for a screening endoscopy before their cancer diagnosis based on the presence and duration of preceding reflux symptoms.
  • METHODS: All patients with adenocarcinoma of the esophagus, adenocarcinoma of the cardia, or long-segment Barrett esophagus presenting for endoscopy at 4 tertiary care and 2 Veterans Affairs (VA) hospitals were given a previously validated questionnaire to determine their recall of common gastroesophageal reflux symptoms.
  • Only 67 of 110 patients (61%) with adenocarcinoma of the esophagus and 8 of 21 patients (38%) with adenocarcinoma of the cardia recalled symptoms of heartburn or regurgitation being present for >5 years before their diagnosis of cancer.
  • Only 40 of 110 patients (36%) with adenocarcinoma of the esophagus and 5 of 21 patients (24%) with adenocarcinoma of the cardia recalled weekly symptoms being present for >5 years before their cancer diagnosis.
  • Of the 244 patients with Barrett esophagus, 170 (70%) recalled heartburn or regurgitation for >5 years and 89 patients (37%) recalled weekly symptoms for >5 years.
  • CONCLUSIONS: Current practice, which uses a screening strategy of performing endoscopy in patients with >5 years of heartburn or regurgitation, can detect Barrett epithelium in only a limited proportion of those patients at risk for developing adenocarcinoma of the esophagus or adenocarcinoma of the cardia.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Cardia / pathology. Esophageal Neoplasms / diagnosis. Gastroesophageal Reflux / diagnosis. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 17019737.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK002800; United States / NIDDK NIH HHS / DK / DK061426; United States / NIDDK NIH HHS / DK / DK070863
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. Rubenstein JH, Vakil N, Inadomi JM: The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma. Aliment Pharmacol Ther; 2005 Jul 15;22(2):135-46
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma.
  • BACKGROUND: The recommended surveillance strategy for oesophageal adenocarcinoma may prevent as few as 50% of cancer deaths.
  • The population consisted of 50-year-old Caucasian men with gastro-oesophageal reflux, who were monitored until age 80.
  • CONCLUSIONS: Biomarkers predicting the development of oesophageal adenocarcinoma would need to be fairly accurate and inexpensive to be cost-effective.
  • These results should guide the development of biomarkers for oesophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers / blood. Esophageal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16011672.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / 1 T32 DK062708
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


33. Kubo A, Corley DA, Jensen CD, Kaur R: Dietary factors and the risks of oesophageal adenocarcinoma and Barrett's oesophagus. Nutr Res Rev; 2010 Dec;23(2):230-46
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary factors and the risks of oesophageal adenocarcinoma and Barrett's oesophagus.
  • Incidence rates for oesophageal adenocarcinoma have increased by over 500% during the past few decades without clear reasons.
  • Gastro-oesophageal reflux disease, obesity and smoking have been identified as risk factors, although the demographic distribution of these risk factors is not consistent with the demographic distribution of oesophageal adenocarcinoma, which is substantially more common among whites and males than any other demographic groups.
  • Numerous epidemiological studies have suggested associations between dietary factors and the risks of oesophageal adenocarcinoma and its precursor, Barrett's oesophagus, though a comprehensive review is lacking.
  • The main aim of the present review is to consider the evidence linking dietary factors with the risks of oesophageal adenocarcinoma, Barrett's oesophagus, and the progression from Barrett's oesophagus to oesophageal adenocarcinoma.
  • The existing epidemiological evidence is strongest for an inverse relationship between intake of vitamin C, β-carotene, fruits and vegetables, particularly raw fruits and vegetables and dark green, leafy and cruciferous vegetables, carbohydrates, fibre and Fe and the risk of oesophageal adenocarcinoma and Barrett's oesophagus.
  • Patients at higher risk for Barrett's oesophagus and oesophageal adenocarcinoma may benefit from increasing their consumption of fruits and vegetables and reducing their intake of red meat and other processed food items.
  • Further research is needed to evaluate the relationship between diet and the progression of Barrett's oesophagus to oesophageal adenocarcinoma.
  • Evidence from cohort studies will help determine whether randomised chemoprevention trials are warranted for the primary prevention of Barrett's oesophagus or its progression to cancer.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Vitamins.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 1998 May;19(5):933-7 [9635885.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2929-34 [9679948.001]
  • [Cites] J Lab Clin Med. 1998 Aug;132(2):134-41 [9708574.001]
  • [Cites] Int J Oncol. 1998 Oct;13(4):855-64 [9735417.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4245-9 [9766645.001]
  • [Cites] Nutr Cancer. 1998;32(1):43-8 [9824856.001]
  • [Cites] Nat Genet. 1999 May;22(1):106-9 [10319873.001]
  • [Cites] Carcinogenesis. 1999 Sep;20(9):1801-8 [10469627.001]
  • [Cites] JPEN J Parenter Enteral Nutr. 1999 Sep-Oct;23(5 Suppl):S89-92 [10483904.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):825-8 [15499620.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jan;3(1):1-10 [15645398.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):190-200 [15654800.001]
  • [Cites] Am J Gastroenterol. 2005 Mar;100(3):568-76 [15743353.001]
  • [Cites] Blood. 2005 Jul 15;106(2):740-5 [15790781.001]
  • [Cites] Cancer Sci. 2005 Sep;96(9):535-42 [16128738.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2377-83 [16214920.001]
  • [Cites] Genet Test. 2005 Fall;9(3):231-41 [16225403.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Nov;3(11):1089-94 [16271339.001]
  • [Cites] Am J Gastroenterol. 2005 Nov;100(11):2599-600 [16279923.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):72-5 [16391374.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):345-54 [16507831.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2559-66 [16380980.001]
  • [Cites] J Am Coll Nutr. 2006 Feb;25(1):64-9 [16522934.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):555-61 [17986316.001]
  • [Cites] Am J Epidemiol. 2008 Apr 1;167(7):839-46 [18218607.001]
  • [Cites] Am J Clin Nutr. 2008 Apr;87(4):949-56 [18400718.001]
  • [Cites] Nutr Cancer. 2008;60(1):39-48 [18444134.001]
  • [Cites] Int J Cancer. 2008 Aug 15;123(4):852-60 [18537156.001]
  • [Cites] Cancer Causes Control. 2008 Aug;19(6):577-84 [18231869.001]
  • [Cites] Int J Occup Environ Health. 2008 Jul-Sep;14(3):193-7 [18686719.001]
  • [Cites] Am J Gastroenterol. 2008 Jul;103(7):1614-23; quiz 1624 [18494834.001]
  • [Cites] Nutrition. 2008 Oct;24(10):941-9 [18562168.001]
  • [Cites] Am J Gastroenterol. 2008 Dec;103(12):2997-3004 [18853987.001]
  • [Cites] Int J Cancer. 2009 Mar 15;124(6):1270-5 [19058177.001]
  • [Cites] Am J Clin Nutr. 2009 Mar;89(3):890-6 [19144726.001]
  • [Cites] Cancer Causes Control. 2009 Apr;20(3):279-88 [18839322.001]
  • [Cites] Gastroenterol Clin North Am. 2009 Mar;38(1):27-57, vii [19327566.001]
  • [Cites] Int J Cancer. 2009 Jul 1;125(1):165-70 [19326432.001]
  • [Cites] Arch Physiol Biochem. 2009 May;115(2):86-96 [19485704.001]
  • [Cites] Surg Oncol Clin N Am. 2009 Jul;18(3):469-85 [19500737.001]
  • [Cites] Int J Cancer. 2009 Sep 1;125(5):1147-54 [19444905.001]
  • [Cites] Nutr Cancer. 2009;61(4):437-46 [19838915.001]
  • [Cites] Nutr Cancer. 2009;61(5):607-16 [19838934.001]
  • [Cites] CA Cancer J Clin. 2009 Nov-Dec;59(6):352-65 [19897839.001]
  • [Cites] J Nutr. 2010 Feb;140(2):317-24 [20032488.001]
  • [Cites] Mol Carcinog. 2010 Mar;49(3):211-4 [20025073.001]
  • [Cites] Gastroenterology. 2010 May;138(5):1704-13 [20006613.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 15):2-8 [10566604.001]
  • [Cites] Pharmacol Res. 2000 Feb;41(2):221-9 [10623490.001]
  • [Cites] Carcinogenesis. 2000 Feb;21(2):257-63 [10657966.001]
  • [Cites] J Gastrointest Surg. 2006 Jun;10(6):870-7 [16769544.001]
  • [Cites] World J Gastroenterol. 2006 Jul 21;12(27):4296-303 [16865769.001]
  • [Cites] Nutr Cancer. 2006;54(2):171-8 [16898861.001]
  • [Cites] J Natl Cancer Inst. 2006 Aug 16;98(16):1158-61 [16912268.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1271-83 [17030196.001]
  • [Cites] World J Gastroenterol. 2007 Mar 14;13(10):1585-94 [17461453.001]
  • [Cites] Cancer Causes Control. 2007 Sep;18(7):713-22 [17562192.001]
  • [Cites] Epidemiol Rev. 2007;29:6-28 [17510091.001]
  • [Cites] Cancer Sci. 2007 Nov;98(11):1683-8 [17868414.001]
  • [Cites] Am J Gastroenterol. 2007 Oct;102(10):2323-30; quiz 2331 [17581269.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2753-60 [17691111.001]
  • [Cites] Am J Prev Med. 2007 Dec;33(6 Suppl):S318-26 [18021906.001]
  • [Cites] Oncol Rep. 2008 Feb;19(2):563-6 [18202808.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):352-8 [18268119.001]
  • [Cites] Br Med Bull. 1999;55(3):578-92 [10746348.001]
  • [Cites] Nutr Cancer. 2000;36(1):7-13 [10798210.001]
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Am J Clin Nutr. 2000 Aug;72(2 Suppl):637S-46S [10919970.001]
  • [Cites] Int J Cancer. 2000 Sep 1;87(5):750-4 [10925371.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):336-41 [11054660.001]
  • [Cites] Gastroenterology. 2001 Feb;120(2):387-91 [11159879.001]
  • [Cites] Proc Nutr Soc. 2001 Feb;60(1):91-106 [11310428.001]
  • [Cites] Nutr Cancer. 2000;38(2):186-91 [11525596.001]
  • [Cites] Eur J Cancer Prev. 2001 Aug;10(4):365-9 [11535879.001]
  • [Cites] J Intern Med. 2001 Oct;250(4):280-90 [11576316.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1055-62 [11588131.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2839-48 [11693316.001]
  • [Cites] Am J Clin Nutr. 2002 Jan;75(1):137-44 [11756071.001]
  • [Cites] Int J Cancer. 2002 Mar 10;98(2):241-56 [11857415.001]
  • [Cites] N Engl J Med. 2002 Mar 14;346(11):836-42 [11893796.001]
  • [Cites] Oncogene. 2002 Sep 5;21(39):6071-81 [12203119.001]
  • [Cites] Nutr Cancer. 2002;42(1):33-40 [12235648.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Oct;128(10):575-80 [12384802.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2096-102 [12412162.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):940-4 [14504209.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):873-7 [14601044.001]
  • [Cites] J Nutr. 2003 Nov;133(11 Suppl 1):3748S-3753S [14608109.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1222-6 [14652285.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2004;44:239-67 [14744246.001]
  • [Cites] Am J Clin Nutr. 2004 Apr;79(4):606-12 [15051604.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):582-8 [15089886.001]
  • [Cites] Lancet. 2004 Apr 24;363(9418):1346-53 [15110491.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):914-9 [15309877.001]
  • [Cites] Science. 1972 Jul 7;177(4043):65-8 [5041776.001]
  • [Cites] N C Med J. 1981 Jul;42(7):467-71 [6265811.001]
  • [Cites] Carcinogenesis. 1983;4(6):755-7 [6861279.001]
  • [Cites] Carcinogenesis. 1985 Dec;6(12):1679-81 [4064244.001]
  • [Cites] Gastroenterology. 1987 Jan;92(1):118-24 [3781178.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Cancer Causes Control. 1991 Nov;2(6):427-42 [1764568.001]
  • [Cites] Cancer Causes Control. 1993 Mar;4(2):123-32 [8481491.001]
  • [Cites] JAMA. 1993 Sep 15;270(11):1320 [8360967.001]
  • [Cites] Am J Physiol. 1994 Jun;266(6 Pt 1):G1090-8 [7912894.001]
  • [Cites] Ann Surg Oncol. 1994 May;1(3):252-61 [7842295.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):104-9 [7707381.001]
  • [Cites] Dig Dis Sci. 1995 Jun;40(6):1292-6 [7781450.001]
  • [Cites] Am J Surg. 1995 Dec;170(6):552-6; discussion 556-7 [7491999.001]
  • [Cites] Am J Gastroenterol. 1996 Aug;91(8):1507-11 [8759651.001]
  • [Cites] J Am Diet Assoc. 1996 Oct;96(10):1027-39 [8841165.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1820-8 [8859198.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):300-4 [8903470.001]
  • [Cites] Int J Cancer. 1997 Mar 28;71(1):14-9 [9096659.001]
  • [Cites] Nutr Cancer. 1997;27(3):298-309 [9101561.001]
  • (PMID = 20624335.001).
  • [ISSN] 1475-2700
  • [Journal-full-title] Nutrition research reviews
  • [ISO-abbreviation] Nutr Res Rev
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK081271-02; United States / NIDDK NIH HHS / DK / F32 DK081271; United States / NIDDK NIH HHS / DK / 5F32DK81271-2; United States / NIDDK NIH HHS / DK / F32 DK081271-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Micronutrients
  • [Other-IDs] NLM/ NIHMS223558; NLM/ PMC3062915
  •  go-up   go-down


34. Mehta S, Johnson IT, Rhodes M: Systematic review: the chemoprevention of oesophageal adenocarcinoma. Aliment Pharmacol Ther; 2005 Nov 1;22(9):759-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systematic review: the chemoprevention of oesophageal adenocarcinoma.
  • The incidence of oesophageal adenocarcinoma is increasing in the UK faster than any other malignancy.
  • Despite its relatively poor prognosis and the limited success of existing treatments, there is enthusiasm that chemopreventive agents might be able to stem the transition from normal squamous epithelium to adenocarcinoma.
  • We discuss gastro-oesophageal reflux as the main risk factor for the development of Barrett's metaplasia, the only known precursor of oesophageal adenocarcinoma.
  • Treatment options for reflux disease are considered with regard to their effects on cancer risk.
  • Available treatments for reflux disease have not convincingly altered the likelihood of cancer development.
  • [MeSH-major] Adenocarcinoma / prevention & control. Esophageal Neoplasms / prevention & control
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Arachidonic Acid / metabolism. Barrett Esophagus / complications. Diet. Disease Progression. Fatty Acids, Omega-3 / metabolism. Gastroesophageal Reflux / complications. Gastroesophageal Reflux / drug therapy. Humans. Nitric Oxide / metabolism. Oxidative Stress / physiology. Proton Pump Inhibitors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16225483.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Fatty Acids, Omega-3; 0 / Proton Pump Inhibitors; 27YG812J1I / Arachidonic Acid; 31C4KY9ESH / Nitric Oxide
  • [Number-of-references] 96
  •  go-up   go-down


35. Van Soest EM, Dieleman JP, Sturkenboom MC, Siersema PD, Kuipers EJ: Gastro-oesophageal reflux, medical resource utilization and upper gastrointestinal endoscopy in patients at risk of oesophageal adenocarcinoma. Aliment Pharmacol Ther; 2008 Jul;28(1):137-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastro-oesophageal reflux, medical resource utilization and upper gastrointestinal endoscopy in patients at risk of oesophageal adenocarcinoma.
  • BACKGROUND: Early identification of patients at risk of oesophageal adenocarcinoma (OAC) might improve survival.
  • AIM: To assess the medical resource utilization in the 3 years before OAC diagnosis as potential markers for early identification and intervention.
  • CONCLUSIONS: Only a minority of all OAC patients used acid inhibitors before diagnosis.
  • The use of medical care between cases and controls differed only in the final year before OAC diagnosis.
  • [MeSH-major] Adenocarcinoma / mortality. Endoscopy, Gastrointestinal / utilization. Esophageal Neoplasms / mortality. Gastroesophageal Reflux / mortality. Resource Allocation / trends
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Barrett Esophagus / diagnosis. Barrett Esophagus / mortality. Case-Control Studies. Female. Humans. Male. Middle Aged. Risk Factors. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18373635.001).
  • [ISSN] 1365-2036
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


36. Rubenstein JH, Taylor JB: Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther; 2010 Nov;32(10):1222-7
MedlinePlus Health Information. consumer health - GERD.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux.
  • BACKGROUND: Endoscopic screening has been proposed for patients with symptoms of gastro-oesophageal reflux disease (GERD) in the hope of reducing mortality from oesophageal adenocarcinoma.
  • Assessing the net benefits of such a strategy requires a precise understanding of the cancer risk in the screened population.
  • AIM: To estimate precisely the association between symptoms of GERD and oesophageal adenocarcinoma.
  • At least weekly symptoms of GERD increased the odds of oesophageal adenocarcinoma fivefold (odds ratio = 4.92; 95% confidence interval = 3.90, 6.22), and daily symptoms increased the odds sevenfold (random effects summary odds ratio = 7.40, 95% confidence interval = 4.94, 11.1), each compared with individuals without symptoms or less frequent symptoms.
  • Duration of symptoms was also associated with oesophageal adenocarcinoma, but with very heterogeneous results, and unclear thresholds.
  • CONCLUSIONS: Frequent GERD symptoms are strongly associated with oesophageal adenocarcinoma.
  • These results should be useful in developing epidemiological models of the development of oesophageal adenocarcinoma, and in models of interventions aimed at reducing mortality from this cancer.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2010. This article is a US Government work and is in the public domain in the USA.
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Gastroenterology. 2010 Jul;139(1):204-12.e3 [20403354.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1888-95 [12190150.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):940-8 [12942560.001]
  • [Cites] JAMA. 1995 Aug 9;274(6):474-7 [7629956.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1028-32 [9672324.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Can J Gastroenterol. 2005 Jan;19(1):15-35 [15685294.001]
  • [Cites] Gastroenterology. 2005 May;128(5):1471-505 [15887129.001]
  • [Cites] BMC Med Res Methodol. 2006;6:50 [17038197.001]
  • [Cites] World J Gastroenterol. 2007 Mar 14;13(10):1585-94 [17461453.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1596-602 [17459024.001]
  • [Cites] Gut. 2008 Feb;57(2):173-80 [17932103.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):352-8 [18268119.001]
  • [Cites] Gut. 2008 Apr;57(4):448-54 [18178609.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] Br J Cancer. 2009 Mar 10;100(5):795-8 [19190630.001]
  • [Cites] Cancer Epidemiol. 2009 Jul;33(1):37-40 [19679045.001]
  • [Cites] Gut. 2009 Dec;58(12):1583-9 [19570765.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • (PMID = 20955441.001).
  • [ISSN] 1365-2036
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K23 DK079291; United States / NIDDK NIH HHS / DK / K23DK079291
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS411964; NLM/ PMC3481544
  •  go-up   go-down


37. Lagergren J, Jansson C: Sex hormones and oesophageal adenocarcinoma: influence of childbearing? Br J Cancer; 2005 Oct 17;93(8):859-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex hormones and oesophageal adenocarcinoma: influence of childbearing?
  • The male predominance of oesophageal adenocarcinoma might be explained by oestrogen protection in women.
  • The influence of childbearing on the risk of oesophageal adenocarcinoma was investigated in a Swedish population-based case (n=63) -control (n=141) study.
  • In conclusion, we found no inverse association between childbearing and oesophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / physiopathology. Esophageal Neoplasms / physiopathology. Estrogens / physiology. Infertility, Female / complications

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Female Infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1459-61 [12168823.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i1-5 [15711002.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jan;3(1):1-10 [15645398.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):913-5 [9796637.001]
  • (PMID = 16189516.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogens
  • [Other-IDs] NLM/ PMC2361653
  •  go-up   go-down


38. Dellon ES, Shaheen NJ: Does screening for Barrett's esophagus and adenocarcinoma of the esophagus prolong survival? J Clin Oncol; 2005 Jul 10;23(20):4478-82
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does screening for Barrett's esophagus and adenocarcinoma of the esophagus prolong survival?
  • Despite the paucity of data supporting its use, screening upper endoscopy for patients with chronic gastroesophageal reflux disease symptoms to assess for Barrett's esophagus and esophageal adenocarcinoma has become a widely accepted practice.
  • We apply the principles of screening to Barrett's esophagus and esophageal adenocarcinoma.
  • The major fault with screening for Barrett's esophagus is that the at-risk population is too broadly characterized and that too many cancers occur outside of this risk pool.
  • Efforts may be better directed at further research identifying groups at risk for esophageal adenocarcinoma, developing more accurate and less-invasive methods of diagnosis, and discovering the underlying factors which continue to drive the increased incidence of this disease.
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus. Esophageal Neoplasms / etiology. Gastroesophageal Reflux / complications. Mass Screening / economics

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16002837.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


39. Lagergren J: Etiology and risk factors for oesophageal adenocarcinoma: possibilities for chemoprophylaxis? Best Pract Res Clin Gastroenterol; 2006;20(5):803-12
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etiology and risk factors for oesophageal adenocarcinoma: possibilities for chemoprophylaxis?
  • The rapid increase in the incidence of oesophageal adenocarcinoma, particularly among white males, seems to be a true increase occurring in many parts of the industrialised world during the last few decades.
  • Barrett's oesophagus, gastrooesophageal reflux, high body mass, male sex, tobacco smoking, and high dietary intake of fruit and vegetables.
  • Several other potential risk factors have been studied for which the evidence is less clear, including medications that relax the lower oesophageal sphincter or diets high in fat or low in nutrients from plant foods.
  • Other factors have been found to be possibly inversely linked with the risk of oesophageal adenocarcinoma, including infection with Helicobacter pylori and anti-inflammatory drugs (such as aspirin and other non-steroidal anti-inflammatory drugs, including cyclo-oxygenase inhibitors).
  • The methodological problem of 'confounding by indication' makes it difficult to interpret the results of anti-inflammatory drugs, and currently such medication cannot be recommended for the prevention of oesophageal adenocarcinoma.
  • Similarly, since there is no strong evidence of a preventive effect of medical or surgical antireflux therapy with regard to risk of oesophageal adenocarcinoma, such therapy cannot be recommended in the prevention of this cancer.
  • Although some of the known risk factors might contribute to the increasing incidence of oesophageal adenocarcinoma, the explanation that can entirely explain this striking trend remains to be identified.
  • Oesophageal adenocarcinoma is a highly deadly cancer, but the overall prognosis and the prognosis after oesophageal cancer surgery has improved during recent years.
  • [MeSH-major] Adenocarcinoma / etiology. Adenocarcinoma / prevention & control. Esophageal Neoplasms / etiology. Esophageal Neoplasms / prevention & control
  • [MeSH-minor] Age Factors. Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Barrett Esophagus / complications. Body Mass Index. Chemoprevention. Esophageal Sphincter, Lower / drug effects. Food Habits. Gastroesophageal Reflux / complications. Gastroesophageal Reflux / therapy. Helicobacter Infections / complications. Helicobacter pylori. Humans. Incidence. Prognosis. Risk Factors. Smoking / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997162.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  • [Number-of-references] 69
  •  go-up   go-down


40. Fitzgerald RC: Genetics and prevention of oesophageal adenocarcinoma. Recent Results Cancer Res; 2005;166:35-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetics and prevention of oesophageal adenocarcinoma.
  • Gastric cancer has been declining for more than half a century, whereas the incidence of oesophageal cancer is increasing rapidly.
  • The histopathological subtype is also changing with a predominance of oesophageal adenocarcinoma compared with squamous carcinoma.
  • The reasons for these epidemiological changes are not clear, although population-based data have implicated gastro-oesophageal reflux disease as a risk factor.
  • In susceptible individuals reflux of duodeno-gastric contents can lead to the development of a columnar-lined oesophagus, commonly called Barrett's oesophagus.
  • This can then progress to adenocarcinoma via a metaplasia-dysplasia-carcinoma sequence.
  • At the current time, the mortality from oesophageal adenocarcinoma exceeds 80% at 5 years.
  • Therefore, endoscopic surveillance programmes have been generally recommended for patients with Barrett's oesophagus in an attempt to detect early, curable lesions.
  • There is mounting evidence that there is an underlying genetic susceptibility to Barrett's oesophagus and oesophageal adenocarcinoma.
  • Once patients are identified as having Barrett's oesophagus their chance for developing adenocarcinoma is in the order of 0.5%-1% per year.
  • The histological assessment of dysplasia as a predictor of cancer development is highly subjective.
  • We have demonstrated an increase in the expression of a novel proliferation marker, Mcm2, which occurs during the malignant progression of Barrett's oesophagus.
  • In view of the role of reflux components in the pathogenesis of Barrett's oesophagus the effect of acid and bile on the cell phenotype have been studied.
  • Given the epidemic increase in oesophageal adenocarcinoma and the dismal 5-year mortality rate, a radical approach is necessary to prevent cancer development in individuals with pre-malignant lesions.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / prevention & control. Esophageal Neoplasms / genetics. Esophageal Neoplasms / prevention & control. Neoplasm Proteins / genetics


41. Heyer CM, Rduch GJ, Zgoura P, Stachetzki U, Voigt E, Nicolas V: Metastasis to skeletal muscle from esophageal adenocarcinoma. Scand J Gastroenterol; 2005 Aug;40(8):1000-4
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis to skeletal muscle from esophageal adenocarcinoma.
  • Diagnosis of an adenocarcinoma of the esophagus was established by endosonography-guided biopsy.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Muscle Neoplasms / secondary. Muscle, Skeletal
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Diagnosis, Differential. Esophagoscopy. Humans. Leg. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16165713.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


42. Jeon J, Luebeck EG, Moolgavkar SH: Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States). Cancer Causes Control; 2006 Sep;17(7):971-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States).
  • A number of hypotheses have been advanced to explain the rapid increase of the incidence of esophageal adenocarcinoma in the US.
  • To address this problem, we have developed multi-stage carcinogenesis models that describe the age-specific incidence of adenocarcinoma of the esophagus and of the gastric cardia with separate adjustments for temporal trends.
  • These models explicitly incorporate important features of the cancers, such as the metaplastic conversion of normal esophagus to Barrett's esophagus (BE).
  • We fit these models separately to the incidence of adenocarcinoma of the esophagus and of the gastric cardia reported in the Surveillance Epidemiology and End Results (SEER) registry over the period 1973-2000.
  • [MeSH-major] Adenocarcinoma / epidemiology. Cardia. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16841264.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA047658; United States / NCI NIH HHS / CA / R01 CA119224-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  •  go-up   go-down


43. Gockel I, Heckhoff S, Messow CM, Kneist W, Junginger T: Transhiatal and transthoracic resection in adenocarcinoma of the esophagus: does the operative approach have an influence on the long-term prognosis? World J Surg Oncol; 2005 Jun 24;3:40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transhiatal and transthoracic resection in adenocarcinoma of the esophagus: does the operative approach have an influence on the long-term prognosis?
  • BACKGROUND: The goal of the present analysis was to investigate the long-term prognosis for adenocarcinoma of the esophagus treated with either the transhiatal (TH) or the transthoracic (TT) operative approach.
  • METHODS: Between September 1985 and March 2004, esophageal resection due to carcinoma was performed on a total of 424 patients.
  • This manuscript takes into account the 150 patients suffering from adenocarcinoma of the esophagus in whom a transhiatal resection of the esophagus was performed.
  • RESULTS: The transthoracic resection of the esophagus demonstrated a higher rate of general complications (p = 0.011) as well as a higher mortality rate (p = 0.011).
  • Considering all of the 150 patients with adenocarcinoma, as well as only those patients who had undergone curative resections (R0), the transhiatal approach was seen to demonstrate a better five-year survival rate of 32.1% versus 35.1%, with a median survival time of 24 versus 28 months, as compared with those who had undergone a transthoracic approach with a five-year survival rate of 13.6% (all patients) versus 17.7% (R0 resection) with a median survival time of 16 versus 17 months (p < 0.05).
  • CONCLUSION: The prognosis in patients with adenocarcinoma of the esophagus is influenced by the depth of the tumor (pT) and the pM-category, as shown in the multivariate analysis.
  • It is questionable, if a more extensive mediastinal lymph node dissection, in addition to the clearance of abdominal lymph nodes, offers prognostic advantages in adenocarcinoma of the esophagus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Jan;11(1):32-7 [9030787.001]
  • [Cites] World J Surg. 1996 May;20(4):507-10 discussion 511 [8662143.001]
  • [Cites] Br J Surg. 1993 Mar;80(3):367-70 [8472154.001]
  • [Cites] Eur J Cardiothorac Surg. 1999 Jun;15(6):769-73 [10431857.001]
  • [Cites] Langenbecks Arch Surg. 1999 Apr;384(2):141-8 [10328167.001]
  • [Cites] Am Surg. 1999 Dec;65(12):1137-41; discussion 1141-2 [10597061.001]
  • [Cites] Onkologie. 2001 Jun;24(3):278-82 [11455222.001]
  • [Cites] Ann Thorac Surg. 2001 Jul;72(1):306-13 [11465217.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2001 Dec;7(6):325-9 [11888470.001]
  • [Cites] Am J Surg. 1997 Sep;174(3):320-4 [9324146.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1662-9 [12444180.001]
  • [Cites] Br J Surg. 1990 Aug;77(8):845-57 [2203505.001]
  • [Cites] Am J Surg. 1989 Nov;158(5):414-9 [2817222.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):364-72; discussion 372-3 [8092902.001]
  • [Cites] Br J Surg. 1994 Mar;81(3):410-3 [8173915.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Aug;106(2):205-9 [8341062.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Feb;105(2):265-76; discussion 276-7 [8429654.001]
  • (PMID = 15978128.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1182399
  •  go-up   go-down


44. Jiménez P, Piazuelo E, Cebrian C, Ortego J, Strunk M, García-Gonzalez MA, Santander S, Alcedo J, Lanas A: Prostaglandin EP2 receptor expression is increased in Barrett's oesophagus and oesophageal adenocarcinoma. Aliment Pharmacol Ther; 2010 Feb 1;31(3):440-51
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostaglandin EP2 receptor expression is increased in Barrett's oesophagus and oesophageal adenocarcinoma.
  • BACKGROUND: Accumulating evidence suggests that cyclooxygenase-2 (COX-2)-derived prostaglandin E2 (PGE2) is involved in oesophageal adenocarcinogenesis.
  • AIM: To investigate which PGE2 receptor subtypes regulate PGE2 signals in the oesophageal adenocarcinoma sequence.
  • METHODS: Expression was determined in oesophageal biopsies from 85 patients with oesophagitis, Barrett's metaplasia, intraepithelial neoplasia, oesophageal adenocarcinoma and normal oesophagus.
  • Expression of EP receptors was also determined in response to acid and bile exposure in the Barrett's adenocarcinoma cell line OE33.
  • RESULTS: All four EP receptors subtypes were expressed in human oesophageal tissues.
  • COX-2 and, especially, EP2 were increased in the Barrett's metaplasia-intraepithelial neoplasia-adenocarcinoma sequence.
  • Expression of the EP4 receptor protein was increased in oesophageal adenocarcinoma.
  • CONCLUSIONS: Our data suggest that in addition to COX-2, EP2 and EP4 receptors could be a selective target in the prevention and/or treatment of the Barrett's-associated adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Cyclooxygenase 1 / metabolism. Esophageal Neoplasms / pathology. RNA, Messenger / metabolism. Receptors, Prostaglandin E / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19843025.001).
  • [ISSN] 1365-2036
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / PTGER2 protein, human; 0 / RNA, Messenger; 0 / Receptors, Prostaglandin E; 0 / Receptors, Prostaglandin E, EP2 Subtype; EC 1.14.99.1 / Cyclooxygenase 1
  •  go-up   go-down


45. Barthel JS, Kucera ST, Lin JL, Hoffe SE, Strosberg JR, Ahmed I, Dilling TJ, Stevens CW: Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus? Gastrointest Endosc; 2010 Feb;71(2):235-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?
  • BACKGROUND: Adenocarcinoma of the esophagus is frequently associated with Barrett's esophagus (BE).
  • The response of esophageal adenocarcinoma to chemoradiation therapy is well described; however, the effect of chemoradiation on tumor-associated BE has not been specifically reported.
  • SETTING: A single National Cancer Institute Comprehensive Cancer Care Center experience.
  • PATIENTS: The study cohort consisted of 43 patients with stage I to IVA esophageal adenocarcinoma associated with BE who received either neoadjuvant or definitive chemoradiation therapy and underwent either esophagectomy or surveillance at our institution.
  • MAIN OUTCOME MEASUREMENT: The presence and extent of BE after chemoradiation therapy of esophageal adenocarcinoma associated with endoscopically documented pretreatment BE.
  • CONCLUSIONS: Chemoradiation therapy of esophageal adenocarcinoma does not eliminate tumor-associated BE, nor does it affect the length of the BE segment.
  • [MeSH-major] Adenocarcinoma / therapy. Barrett Esophagus / therapy. Esophageal Neoplasms / therapy. Esophagoscopy. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] C
  • (PMID = 20003971.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Barclay JY, Morris A, Nwokolo CU: Telomerase, hTERT and splice variants in Barrett's oesophagus and oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol; 2005 Feb;17(2):221-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase, hTERT and splice variants in Barrett's oesophagus and oesophageal adenocarcinoma.
  • BACKGROUND AND OBJECTIVES: The enzyme telomerase is re-activated in most cancers but its mechanism of regulation in oesophageal carcinogenesis is unclear.
  • The aim of this study was to determine the roles of human telomerase reverse transcriptase (hTERT) mRNA expression and hTERT mRNA splicing in the regulation of telomerase enzyme activity in Barrett's oesophagus and oesophageal adenocarcinoma.
  • METHODS: Paired samples from oesophageal adenocarcinoma (n=21) and adjacent macroscopically normal mucosa, and paired samples from Barrett's oesophagus (n=16) and adjacent cardia mucosa were obtained.
  • RESULTS: In oesophageal adenocarcinoma, compared to adjacent mucosa, median telomerase activity increased significantly (from 5 to 229 total product generated (tpg), P=0.0002), but median hTERT mRNA levels were not significantly different.
  • Similarly, median telomerase activity was significantly higher in oesophageal adenocarcinoma compared to Barrett's oesophagus (229 vs 20 tpg, P=0.001), but hTERT mRNA levels were not significantly different.
  • There was no significant difference in telomerase activity and hTERT mRNA levels between Barrett's oesophagus and adjacent cardia.
  • The frequency of detection of all variants increased from cardia to Barrett's oesophagus to oesophageal adenocarcinoma (P<0.05).
  • CONCLUSIONS: A major increase in telomerase activity occurs after the Barrett's oesophagus stage in oesophageal carcinogenesis.
  • In this cancer, an important clinical diagnostic role for the transcripts of the telomerase gene is improbable.
  • [MeSH-major] Adenocarcinoma / enzymology. Barrett Esophagus / enzymology. Esophageal Neoplasms / enzymology. Gene Expression Regulation, Neoplastic. Telomerase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15674101.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


47. Zhang X, Watson DI, Jamieson GG: Lymph node metastases of adenocarcinoma of the esophagus and esophagogastric junction. Chin Med J (Engl); 2007 Dec 20;120(24):2268-70
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node metastases of adenocarcinoma of the esophagus and esophagogastric junction.
  • BACKGROUND: Esophageal adenocarcinoma is becoming an increasingly important problem.
  • The aim of this study was to evaluate the relationship between tumor invasion depth and lymph node metastasis for adenocarcinoma of the esophagus and esophagogastric junction, and to analyze the impact of lymph node metastases on survival of the patients.
  • METHODS: The study group comprised 121 patients with adenocarcinoma of the esophagus or esophagogastric junction, who underwent esophagectomy between January 1985 and December 2003 at either the Royal Adelaide Hospital or the Flinders Medical Center, Australia.
  • RESULTS: The tumors were located entirely within the esophagus in 83 patients, and involved the gastro-esophageal junction in 38.
  • When tumor invasion was within mucosa or submucosa of the esophagus (T1), the lymph node metastasis rate was 22.2% (10/45), the mean number of metastatic lymph nodes was 0.3, and the proportion of more than 4 lymph nodes metastases was 0% (0/45).
  • When tumor invaded the adjacent structures of the esophagus (T4), the lymph node metastasis rate was 85.7% (6/7); the mean number of metastatic lymph nodes was 5.1, and the proportion of more than 4 lymph nodes metastases was 71.4% (5/7).
  • CONCLUSIONS: There is a close association between tumor invasion depth and lymph node metastasis for adenocarcinoma of the esophagus and esophagogastric junction.
  • Moreover, when the tumor invades deeper into the esophageal wall, the percentage of patients with more than 4 involved nodes increases.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18167216.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


48. Cooper GS, Kou TD, Chak A: Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. Am J Gastroenterol; 2009 Jun;104(6):1356-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends.
  • OBJECTIVES: Endoscopic screening of the at-risk population with chronic gastroesophageal reflux disease (GERD) for the presence of intestinal metaplasia or Barrett's esophagus has been suggested as a method to reduce mortality from esophageal adenocarcinoma.
  • METHODS: All patients aged 68 years and older with a new diagnosis of adenocarcinoma of the esophagus from 1994 to 2002 were identified from a linked tumor registry health claims database.
  • Using claims from 1991 to 2002, the use of endoscopy as well as a diagnosis of GERD or Barrett's esophagus during the time interval from 3 years through 6 months prior to diagnosis were measured.
  • The association of these measures with early-stage cancer (in situ, local) and long-term survival was determined, as well as changes over time.
  • Previous endoscopy had been performed in 11.5% of patients, and GERD and Barrett's esophagus diagnoses were recorded in 22.4 and 8.1% of patients, respectively.
  • Barrett's esophagus diagnosis was strongly associated with both early-stage cancer (odds ratio 3.68, confidence interval (CI) 1.30-10.40) and survival (hazard ratio 0.45, CI 0.25-0.80).
  • A GERD diagnosis was associated only with early stage, and endoscopy was associated only with survival.
  • There was no association of year of diagnosis with stage or survival.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endoscopy, Gastrointestinal / methods. Esophageal Neoplasms / diagnosis. SEER Program / trends
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Incidence. Male. Neoplasm Staging / methods. Prognosis. Retrospective Studies. Risk Factors. Survival Rate / trends. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Gastroenterol. 2009 Dec;104(12):3106-7; author reply 3107-8 [19956133.001]
  • [CommentIn] Am J Gastroenterol. 2009 Oct;104(10):2632-3; author reply 2633 [19806097.001]
  • [CommentIn] Am J Gastroenterol. 2009 Jun;104(6):1363-5 [19436281.001]
  • (PMID = 19491849.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K05 CA 90677; United States / NIDDK NIH HHS / DK / K24 DK 02800
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


49. Anderson LA, Watson RG, Murphy SJ, Johnston BT, Comber H, Mc Guigan J, Reynolds JV, Murray LJ: Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol; 2007 Mar 14;13(10):1585-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study.
  • AIM: To investigate risk factors associated with Barrett's oesophagus and oesophageal adenocarcinoma.
  • METHODS: This all-Ireland population-based case-control study recruited 224 Barrett's oesophagus patients, 227 oesophageal adenocarcinoma patients and 260 controls.
  • RESULTS: Gastro-oesophageal reflux was associated with Barrett's [OR 12.0 (95% CI 7.64-18.7)] and oesophageal adenocarcinoma [OR 3.48 (95% CI 2.25-5.41)].
  • Oesophageal adenocarcinoma patients were more likely than controls to be ex- or current smokers [OR 1.72 (95% CI 1.06-2.81) and OR 4.84 (95% CI 2.72-8.61) respectively] and to have a high body mass index [OR 2.69 (95% CI 1.62-4.46)].
  • No significant associations were observed between these risk factors and Barrett's oesophagus.
  • Fruit but not vegetables were negatively associated with oesophageal adenocarcinoma [OR 0.50 (95% CI 0.30-0.86)].
  • CONCLUSION: A high body mass index, a diet low in fruit and cigarette smoking may be involved in the progression from Barrett's oesophagus to oesophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Barrett Esophagus / epidemiology. Esophageal Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Prev. 1995 Dec;4(6):459-68 [8580781.001]
  • [Cites] World Health Organ Tech Rep Ser. 1995;854:1-452 [8594834.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):295-9 [8903469.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):300-4 [8903470.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92(2):212-5 [9040193.001]
  • [Cites] Am J Gastroenterol. 1997 Aug;92(8):1293-7 [9260792.001]
  • [Cites] Neurology. 1997 Aug;49(2):507-11 [9270586.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Am J Gastroenterol. 1998 Apr;93(4):536-41 [9576444.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):86-91 [9934736.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Am J Med. 1999 Jun;106(6):642-9 [10378622.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Nutr Cancer. 2002;42(1):33-40 [12235648.001]
  • [Cites] JAMA. 2002 Oct 9;288(14):1723-7 [12365955.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Oct;128(10):575-80 [12384802.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3467S-3470S [12421872.001]
  • [Cites] IARC Sci Publ. 2002;156:123-5 [12484143.001]
  • [Cites] JAMA. 2003 Jul 2;290(1):66-72 [12837713.001]
  • [Cites] Int J Epidemiol. 2003 Aug;32(4):645-50 [12913045.001]
  • [Cites] Am J Clin Nutr. 2003 Sep;78(3 Suppl):559S-569S [12936950.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):940-8 [12942560.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):534-5 [12958113.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] World J Surg. 2003 Sep;27(9):999-1008; discussion 1006-8 [12917764.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):975-82 [14608530.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):849-56; discussion 856-8 [15166964.001]
  • [Cites] Biomarkers. 2003 Nov-Dec;8(6):509-21 [15195681.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):579-91 [15286738.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):914-9 [15309877.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2037-42 [10445525.001]
  • [Cites] Br J Cancer. 1999 Jul;80 Suppl 1:95-103 [10466767.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5A):3029-34 [15517912.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4975-82 [16651456.001]
  • [Cites] Dis Esophagus. 2000;13(1):28-31 [11005328.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):962-6 [11020858.001]
  • [Cites] Eur J Cancer Prev. 2001 Aug;10(4):365-9 [11535879.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):721-32 [11562112.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1055-62 [11588131.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):620-5 [15767340.001]
  • [Cites] Rom J Gastroenterol. 2005 Jun;14(2):117-21 [15990929.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2151-6 [16181362.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2481-6 [16284367.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2559-66 [16380980.001]
  • [Cites] JAMA. 1999 Oct 27;282(16):1519-22 [10546690.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 15):2-8 [10566604.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):340-6 [10652424.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2520-8 [10861428.001]
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] Int J Cancer. 2000 Sep 1;87(5):750-4 [10925371.001]
  • [Cites] Am J Clin Nutr. 2002 Jan;75(1):137-44 [11756071.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):225-9 [11774268.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):26-33 [11781277.001]
  • [Cites] Public Health Nutr. 2001 Oct;4(5A):1037-42 [11820916.001]
  • [Cites] Public Health Nutr. 2001 Oct;4(5A):1099-106 [11820923.001]
  • [Cites] Surg Endosc. 2002 Apr;16(4):671-3 [11972212.001]
  • [Cites] Proc Nutr Soc. 2002 Feb;61(1):3-7 [12002792.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1328-31 [12094845.001]
  • [Cites] Obes Rev. 2002 Feb;3(1):9-15 [12119661.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6365-78 [15322511.001]
  • [Cites] Br Med J. 1972 Sep 30;3(5830):793-5 [5076250.001]
  • [Cites] N Engl J Med. 1985 Oct 3;313(14):857-9 [4033716.001]
  • [Cites] Am J Gastroenterol. 1989 Dec;84(12):1494-6 [2596449.001]
  • [Cites] Gut. 1990 Jan;31(1):4-10 [2318431.001]
  • [Cites] Gastroenterology. 1990 Oct;99(4):918-22 [2394347.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7415-21 [2174724.001]
  • [Cites] Eur J Cancer Prev. 1992 Feb;1(2):159-64 [1463978.001]
  • [Cites] Eur J Cancer Prev. 1992 Apr;1(3):265-9 [1467772.001]
  • [Cites] Cancer Causes Control. 1993 Mar;4(2):123-32 [8481491.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):402-7 [8509215.001]
  • [Cites] Cancer Causes Control. 1994 Jul;5(4):333-40 [8080945.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):104-9 [7707381.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Mar;4(2):85-92 [7742727.001]
  • [Cites] JAMA. 1995 Aug 9;274(6):474-7 [7629956.001]
  • (PMID = 17461453.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4146903
  •  go-up   go-down


50. Biondi A, Migliore M, Strano G, Vadala S, Tropea A, Basile F: Clinical biomarkers in esophageal adenocarcinoma. Front Biosci (Elite Ed); 2010;2:489-94
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical biomarkers in esophageal adenocarcinoma.
  • This review describes genetic and molecular changes related to adenocarcinoma of the esophagus and gastroesophageal junction (GEJ) with emphasis on prognostic value and possibilities for targeted therapy in clinical setting.
  • The progression of Barrett's esophagus to adenocarcinoma has been the focus of particular scrutiny, and a number of potential tissue and serum-based disease biomarkers have emerged.
  • Tissue biomarkers allowing risk stratification of Barrett's are reviewed as well as strategies currently being used to discover novel biomarkers that will facilitate the early detection of esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Esophageal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20036895.001).
  • [ISSN] 1945-0508
  • [Journal-full-title] Frontiers in bioscience (Elite edition)
  • [ISO-abbreviation] Front Biosci (Elite Ed)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers
  • [Number-of-references] 45
  •  go-up   go-down


51. Wong RK, Altekruse SF: Where are you and how do we find you? The dilemma of identifying Barrett's epithelium before adenocarcinoma of the esophagus. Am J Gastroenterol; 2009 Jun;104(6):1363-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Where are you and how do we find you? The dilemma of identifying Barrett's epithelium before adenocarcinoma of the esophagus.
  • The incidence of esophageal adenocarcinoma in white males has been increasing steadily over the past decade.
  • However, attempts to identify the precursor lesion, intestinal metaplasia of the esophagus, or early in-situ cancers have been dismal, with no increase in the diagnosis of early cancers over 9 years of follow-up, as noted in the study by Cooper et al.
  • Important predictors of survival,such as a previous diagnosis of gastroesophageal reflux disease, endoscopy, and the diagnosis of intestinal metaplasia, continue to represent a minority of patients who present with esophageal adenocarcinoma.
  • Over time, factors that encourage localized, distal esophageal reflux may be the insidious culprit that leads to intestinal metaplasia.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Intestinal Mucosa / pathology. Precancerous Conditions / pathology. SEER Program

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Gastroenterol. 2009 Jun;104(6):1356-62 [19491849.001]
  • (PMID = 19436281.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


52. van Blankenstein M, Looman CW, Siersema PD, Kuipers EJ, Coebergh JW: Trends in the incidence of adenocarcinoma of the oesophagus and cardia in the Netherlands 1989-2003. Br J Cancer; 2007 Jun 4;96(11):1767-71
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in the incidence of adenocarcinoma of the oesophagus and cardia in the Netherlands 1989-2003.
  • Over the 15-year period 1989-2003, the incidence of oesophagus-cardia adenocarcinoma in the Netherlands rose annually by 2.6% for males and 1.2% for females.
  • This was the net outcome of annual increases in the incidence of adenocarcinoma of the oesophagus (ACO) of 7.2% for males and 3.5% for females and annual declines in the incidence of adenocarcinoma of the gastric cardia (AGC) of more than 1% for both genders.
  • [MeSH-major] Adenocarcinoma / epidemiology. Cardia. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1415-25 [11821356.001]
  • [Cites] Clin Ther. 2001 Dec;23(12):1984-98 [11813933.001]
  • [Cites] Bull World Health Organ. 2002;80(1):26-32 [11884970.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1518-20 [11984536.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):60-7 [12105834.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):421-40, viii [12134611.001]
  • [Cites] Int J Obes Relat Metab Disord. 2002 Sep;26(9):1218-24 [12187399.001]
  • [Cites] Int J Cancer. 2003 Mar 1;103(6):815-21 [12516104.001]
  • [Cites] Eur J Clin Pharmacol. 2003 Sep;59(5-6):477-82 [12937872.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(17):2487-94 [14602134.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):34-9 [14744730.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):340-6 [10652424.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5767-72 [11059772.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Jan;16(1):69-74 [15095855.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Sep;16(9):903-9 [15316416.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Sep 15;20(6):645-55 [15352913.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Oct;2(10):880-7 [15476151.001]
  • [Cites] J Thorac Cardiovasc Surg. 1975 Nov;70(5):826-35 [1186274.001]
  • [Cites] Am J Clin Pathol. 1978 Jul;70(1):1-5 [696666.001]
  • [Cites] Stat Med. 1987 Jun;6(4):449-67 [3629047.001]
  • [Cites] Stat Med. 1987 Jun;6(4):469-81 [3629048.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Jul;112(1):130-6 [8691857.001]
  • [Cites] Am J Gastroenterol. 1997 Sep;92(9):1480-2 [9317067.001]
  • [Cites] Am J Gastroenterol. 1998 Oct;93(10):1800-2 [9772034.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):86-91 [9934736.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):529-35 [10215831.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):353-60 [10365894.001]
  • [Cites] Int J Epidemiol. 1999 Jun;28(3):391-5 [10405839.001]
  • [Cites] Br J Cancer. 1952 Jun;6(2):127-30 [14954081.001]
  • [Cites] Gut. 2005 Jan;54(1):1-3 [15591495.001]
  • [Cites] Am J Gastroenterol. 2005 Apr;100(4):766-74 [15784017.001]
  • [Cites] Gut. 2005 Aug;54(8):1062-6 [15857935.001]
  • [Cites] Ann Intern Med. 2005 Aug 2;143(3):199-211 [16061918.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2151-6 [16181362.001]
  • [Cites] Gut. 2005 Nov;54(11):1527-35 [16227357.001]
  • [Cites] CA Cancer J Clin. 2005 Nov-Dec;55(6):334-51 [16282279.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):945-52 [16321762.001]
  • [Cites] Ned Tijdschr Geneeskd. 2005 Dec 10;149(50):2775-82 [16385829.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):687-96 [16997153.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] Gut. 2002 Mar;50(3):368-72 [11839716.001]
  • (PMID = 17505507.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2359916
  •  go-up   go-down


53. Kirkeleit J, Riise T, Bjørge T, Moen BE, Bråtveit M, Christiani DC: Increased risk of oesophageal adenocarcinoma among upstream petroleum workers. Occup Environ Med; 2010 May;67(5):335-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk of oesophageal adenocarcinoma among upstream petroleum workers.
  • OBJECTIVES: To investigate cancer risk, particularly oesophageal cancer, among male upstream petroleum workers offshore potentially exposed to various carcinogenic agents.
  • The historical cohort was linked to the Cancer Registry of Norway and the Norwegian Cause of Death Registry.
  • RESULTS: Male offshore workers had excess risk of oesophageal cancer (RR 2.6, 95% CI 1.4 to 4.8) compared with the reference population.
  • Only the adenocarcinoma type had a significantly increased risk (RR 2.7, 95% CI 1.0 to 7.0), mainly because of an increased risk among upstream operators (RR 4.3, 95% CI 1.3 to 14.5).
  • Upstream operators did not have significant excess of respiratory system or colon cancer or mortality from any other lifestyle-related diseases investigated.
  • CONCLUSION: We found a fourfold excess risk of oesophageal adenocarcinoma among male workers assumed to have had the most extensive contact with crude oil.
  • Due to the small number of cases, and a lack of detailed data on occupational exposure and lifestyle factors associated with oesophageal adenocarcinoma, the results must be interpreted with caution.
  • Nevertheless, given the low risk of lifestyle-related cancers and causes of death in this working group, the results add to the observations in other low-powered studies on oesophageal cancer, further suggesting that factors related to the petroleum stream or carcinogenic agents used in the production process might be associated with risk of oesophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / epidemiology. Occupational Diseases / epidemiology. Occupational Exposure / adverse effects. Petroleum / toxicity

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1983 Feb 26;1(8322):462-3 [6131179.001]
  • [Cites] Occup Environ Med. 2008 Nov;65(11):774-81 [18614460.001]
  • [Cites] Am J Ind Med. 2001 Feb;39(2):121-32 [11170155.001]
  • [Cites] J Occup Environ Med. 2001 Feb;43(2):133-9 [11227631.001]
  • [Cites] Occup Environ Med. 2002 Apr;59(4):248-56 [11934952.001]
  • [Cites] Ann Epidemiol. 2003 Jan;13(1):50-6 [12547485.001]
  • [Cites] Occup Environ Med. 2003 Dec;60(12):918-28 [14634182.001]
  • [Cites] Am J Epidemiol. 2003 Dec 15;158(12):1182-92 [14652303.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] Int J Cancer. 2004 Aug 20;111(2):286-92 [15197784.001]
  • [Cites] Cancer Causes Control. 2004 Oct;15(8):837-43 [15456997.001]
  • [Cites] J Occup Med. 1979 Mar;21(3):167-74 [438906.001]
  • [Cites] Br J Ind Med. 1993 May;50(5):450-9 [8507598.001]
  • [Cites] Arch Environ Health. 1993 Jul-Aug;48(4):243-5 [8357273.001]
  • [Cites] Scand J Work Environ Health. 1994 Oct;20(5):331-8 [7863296.001]
  • [Cites] Am J Ind Med. 1998 Jul;34(1):36-48 [9617386.001]
  • [Cites] Occup Environ Med. 1998 Jun;55(6):393-400 [9764099.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Int J Cancer. 2005 Apr 10;114(3):479-83 [15578719.001]
  • [Cites] Cancer Causes Control. 2005 Aug;16(6):755-64 [16049815.001]
  • [Cites] Am J Ind Med. 2005 Oct;48(4):249-58 [16167347.001]
  • [Cites] Occup Environ Med. 2006 Feb;63(2):107-12 [16421388.001]
  • [Cites] Am J Epidemiol. 2006 Apr 15;163(8):717-25 [16467414.001]
  • [Cites] Occup Environ Med. 2006 Jul;63(7):476-81 [16698808.001]
  • [Cites] Lancet. 2006 Jul 29;368(9533):367-70 [16876664.001]
  • [Cites] Occup Environ Med. 2007 Apr;64(4):250-8 [17043075.001]
  • [Cites] Occup Med (Lond). 2007 May;57(3):177-85 [17244595.001]
  • [Cites] Occup Environ Med. 2007 Sep;64(9):616-25 [17449563.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2090-6 [17890521.001]
  • [Cites] Gut. 2007 Nov;56(11):1503-11 [17337464.001]
  • [Cites] Int J Cancer. 2008 Mar 1;122(5):1118-29 [17990321.001]
  • [Cites] Cancer Causes Control. 2008 Feb;19(1):13-23 [17906934.001]
  • [Cites] Int J Cancer. 2008 Sep 15;123(6):1422-8 [18546259.001]
  • [Cites] Occup Environ Med. 2000 Jun;57(6):411-7 [10810131.001]
  • (PMID = 19858535.001).
  • [ISSN] 1470-7926
  • [Journal-full-title] Occupational and environmental medicine
  • [ISO-abbreviation] Occup Environ Med
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA074386; United States / NCI NIH HHS / CA / R01 CA074386-03; United States / NCI NIH HHS / CA / R01 CA074386-04; United States / NCI NIH HHS / CA / R01 CA074386-05; United States / NCI NIH HHS / CA / R01 CA074386-06A1; United States / NCI NIH HHS / CA / R01 CA074386-07; United States / NCI NIH HHS / CA / R01 CA074386-08; United States / NCI NIH HHS / CA / R01 CA074386-09; United States / NCI NIH HHS / CA / R01 CA074386-10
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Petroleum
  • [Other-IDs] NLM/ NIHMS493408; NLM/ PMC3728278
  •  go-up   go-down


54. Peters CJ, Fitzgerald RC: Systematic review: the application of molecular pathogenesis to prevention and treatment of oesophageal adenocarcinoma. Aliment Pharmacol Ther; 2007 Jun 01;25(11):1253-69
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systematic review: the application of molecular pathogenesis to prevention and treatment of oesophageal adenocarcinoma.
  • BACKGROUND: Oesophageal adenocarcinoma is an increasingly common cancer with a poor prognosis.
  • It develops in a stepwise progression from Barrett's metaplasia to dysplasia, and then adenocarcinoma followed by metastasis.
  • AIM: To outline the key molecular changes in oesophageal adenocarcinoma and to summarize the chemopreventative and therapeutic strategies proposed.
  • Search terms included: Barrett's (o)esophagus, intestinal metaplasia, (o)esophageal adenocarcinoma, molecular changes, genetic changes, pathogenesis, chemoprevention, therapeutic strategies and treatment.
  • RESULTS: A large number of molecular changes have been identified in the progression from Barrett's oesophagus to oesophageal adenocarcinoma although there does not appear to be an obligate order of events.
  • In established adenocarcinoma, targeted treatments under evaluation include receptor tyrosine kinase inhibitors of EGFR and cyclin-dependent kinase inhibitors, which may benefit a subgroup of patients.
  • CONCLUSIONS: Advances in molecular methodology have led to a greater understanding of the oesophageal adenocarcinoma pathways, which provides opportunities for chemoprevention and therapeutic strategies with a mechanistic basis.
  • [MeSH-major] Adenocarcinoma / prevention & control. Angiogenesis Inhibitors / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Antioxidants / therapeutic use. Esophageal Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509094.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105365007
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Anti-Inflammatory Agents; 0 / Antioxidants
  • [Number-of-references] 149
  •  go-up   go-down


55. Lagarde SM, de Boer JD, ten Kate FJ, Busch OR, Obertop H, van Lanschot JJ: Postoperative complications after esophagectomy for adenocarcinoma of the esophagus are related to timing of death due to recurrence. Ann Surg; 2008 Jan;247(1):71-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative complications after esophagectomy for adenocarcinoma of the esophagus are related to timing of death due to recurrence.
  • After esophagectomy for adenocarcinoma of the distal esophagus and/or gastroesophageal junction, the majority of patients develops an early recurrence and dies within 2 years.
  • METHODS: A consecutive series of 351 patients who underwent esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction was reviewed.
  • RESULTS: Of the 351 included patients, 191 patients (54%) died due to recurrence of esophageal adenocarcinoma.
  • Multivariate Cox regression analysis demonstrated that T-stage, lymph node ratio >0.20, the presence of extracapsular lymph node involvement, but not complications were significant factors for the prediction of death due to cancer recurrence.
  • CONCLUSION: The relation between perioperative complications and cancer recurrence per se is not causal.
  • However, postoperative complications are independently associated with the early timing of death due to cancer recurrence.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Esophageal Neoplasms / mortality. Esophageal Neoplasms / surgery. Esophagectomy. Neoplasm Recurrence, Local / mortality. Postoperative Complications / mortality

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156925.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


56. Neale RE, Doecke JD, Pandeya N, Sadeghi S, Green AC, Webb PM, Whiteman DC, Australian Cancer Study: Does type 2 diabetes influence the risk of oesophageal adenocarcinoma? Br J Cancer; 2009 Mar 10;100(5):795-8
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does type 2 diabetes influence the risk of oesophageal adenocarcinoma?
  • Since hyperinsulinaemia may promote obesity-linked cancers, we compared type 2 diabetes prevalence among oesophageal adenocarcinoma (OAC) patients and population controls.
  • [MeSH-major] Adenocarcinoma / etiology. Diabetes Mellitus, Type 2 / complications. Esophageal Neoplasms / etiology

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Diabetes, Type 2.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Cancer Causes Control. 2001 Dec;12(10):943-9 [11808714.001]
  • [Cites] Oncol Rep. 2003 Nov-Dec;10(6):2015-21 [14534736.001]
  • [Cites] Int J Obes Relat Metab Disord. 2004 May;28(5):710-8 [15007395.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):849-56; discussion 856-8 [15166964.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):579-91 [15286738.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Aug 1;22(3):267-71 [16091065.001]
  • [Cites] BMJ. 2007 Dec 1;335(7630):1134 [17986716.001]
  • [Cites] Gut. 2008 Feb;57(2):173-80 [17932103.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):352-8 [18268119.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1169-78 [18483339.001]
  • [Cites] Int J Mol Med. 2000 Apr;5(4):421-6 [10719061.001]
  • [ErratumIn] Br J Cancer. 2009 May 5;100(9):1514. Sadhegi, S [corrected to Sadeghi, S]
  • (PMID = 19190630.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2653775
  • [Investigator] Whiteman DC; Webb PM; Green AC; Hayward NK; Parsons PG; Purdie DM
  •  go-up   go-down


57. Goddeeris K, Verslype C, Wilms G, Van Cutsem E: Leptomeningeal carcinomatosis associated with oesophageal adenocarcinoma: two case reports and review of the literature. Acta Gastroenterol Belg; 2006 Oct-Dec;69(4):377-80
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal carcinomatosis associated with oesophageal adenocarcinoma: two case reports and review of the literature.
  • We report two cases of leptomeningeal carcinomatosis in patients with oesophageal adenocarcinoma.
  • Diagnosis of LC can be overlooked without a high index of suspicion.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Meningeal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343079.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


58. Lamb PJ, Griffin SM, Burt AD, Lloyd J, Karat D, Hayes N: Sentinel node biopsy to evaluate the metastatic dissemination of oesophageal adenocarcinoma. Br J Surg; 2005 Jan;92(1):60-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel node biopsy to evaluate the metastatic dissemination of oesophageal adenocarcinoma.
  • BACKGROUND: The aim of this study was to determine the feasibility and accuracy of sentinel lymph node (SLN) biopsy for oesophageal adenocarcinoma.
  • METHODS: Fifty-seven patients with adenocarcinoma of the lower oesophagus (n = 40) or gastric cardia (n = 17) underwent endoscopic peritumoral injection of (99m)Tc-radiolabelled nanocolloid before en bloc resection with extended lymphadenectomy.
  • Lower oesophageal tumours had a greater proportion of SLNs (P = 0.018), radioactive uptake (P < 0.001) and malignant nodes (P = 0.004) in the mediastinum than gastric cardia tumours.
  • CONCLUSION: The sentinel node concept is applicable to oesophageal adenocarcinoma and could be used to tailor the extent of lymphadenectomy.
  • There is a close relationship between patterns of radioactive uptake and lymphatic tumour dissemination, which differ for lower oesophageal and gastric cardia tumours.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Sentinel Lymph Node Biopsy / methods. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15584066.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


59. Shibata A, Matsuda T, Ajiki W, Sobue T: Trend in incidence of adenocarcinoma of the esophagus in Japan, 1993-2001. Jpn J Clin Oncol; 2008 Jul;38(7):464-8
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trend in incidence of adenocarcinoma of the esophagus in Japan, 1993-2001.
  • BACKGROUND: Several studies with population-based cancer registry data have suggested that incidence of adenocarcinoma of the esophagus has been increasing since 1970 in some European and North American countries and Australia.
  • However, data from Asian countries with regard to the incidence of esophageal cancer by histological type based on the population-based cancer registry are lacking.
  • The aim of this study was to describe the incidence of esophageal cancer by histological type in a Japanese population.
  • METHODS: Cancer incidence data for 1993-2001 from 15 population-based cancer registries were collected by the Japan Cancer Surveillance Research Group in 2005.
  • RESULTS: Squamous cell carcinoma remains the predominant type in all esophageal cancers in Japan.
  • The ratio of squamous cell carcinoma to adenocarcinoma is 26:1.
  • For adenocarcinoma, estimated average annual percentage change was 4.7% (95% confidence interval: 0.7, 8.9) in men and 6.0% (2.4, 9.8) in women.
  • CONCLUSION: No dramatic increase in adenocarcinoma has occurred, and absolute incidence remains low in Japan.
  • [MeSH-major] Adenocarcinoma / epidemiology. Asian Continental Ancestry Group / statistics & numerical data. Esophageal Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18664481.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


60. Mitchell EM, Pal N, Kalyan JP, Rhodes M, Lewis MP: Poor outcome of oesophageal adenocarcinoma after prior antireflux surgery. Int J Surg; 2009 Dec;7(6):566-9
MedlinePlus Health Information. consumer health - GERD.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor outcome of oesophageal adenocarcinoma after prior antireflux surgery.
  • AIMS: Gastro-oesophageal reflux disease is an important risk factor for oesophageal adenocarcinoma, but abolishing reflux through surgery has not been shown to reduce this risk.
  • PATIENTS AND METHODS: Six hundred and forty three patients underwent surgical resection in our unit for oesophagogastric adenocarcinoma between 2000 and 2009.
  • CONCLUSIONS: Patients who have undergone antireflux surgery for chronic gastro-oesophageal reflux disease can develop adenocarcinoma and need to be monitored closely.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Cause of Death. Esophageal Neoplasms / mortality. Esophageal Neoplasms / surgery. Gastroesophageal Reflux / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19833239.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


61. Rutegård M, Nordenstedt H, Lu Y, Lagergren J, Lagergren P: Sex-specific exposure prevalence of established risk factors for oesophageal adenocarcinoma. Br J Cancer; 2010 Aug 24;103(5):735-40
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex-specific exposure prevalence of established risk factors for oesophageal adenocarcinoma.
  • BACKGROUND: There is an unexplained male predominance in the incidence of oesophageal adenocarcinoma, and the sex-specific distribution of its risk factors in the general population is not known.
  • METHODS: A random sample of Swedish citizens aged 40-79 years completed a questionnaire for assessment of the prevalence of five risk factors for oesophageal adenocarcinoma: reflux symptoms, body mass index, tobacco smoking habits, socioeconomic status, and use of non-steroidal anti-inflammatory drugs (NSAIDs).
  • CONCLUSIONS: Exposure to some but not all established risk factors for oesophageal adenocarcinoma seems to be more common in men than in women, but the differences are small and unlikely to explain the male predominance of this tumour.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):913-5 [9796637.001]
  • [Cites] Acta Unio Int Contra Cancrum. 1953;9(3):531-41 [13124110.001]
  • [Cites] Scand J Gastroenterol. 2004 Nov;39(11):1040-5 [15545159.001]
  • [Cites] J Health Econ. 2004 Jul;23(4):653-61 [15587692.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):285-94 [15947880.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1754-61 [16030113.001]
  • [Cites] Ann Intern Med. 2005 Aug 2;143(3):199-211 [16061918.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):859-61 [16189516.001]
  • [Cites] Am J Epidemiol. 2005 Dec 1;162(11):1050-61 [16221805.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):136-41 [16404367.001]
  • [Cites] JAMA. 2006 Apr 5;295(13):1549-55 [16595758.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):872-8 [16702363.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1151-8 [16630714.001]
  • [Cites] Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943 [16928254.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1277-9 [17060932.001]
  • [Cites] Dig Dis Sci. 2006 Dec;51(12):2292-301 [17089189.001]
  • [Cites] Eur J Public Health. 2007 Apr;17(2):125-33 [16751631.001]
  • [Cites] Am J Epidemiol. 2007 Jun 15;165(12):1424-33 [17420181.001]
  • [Cites] Public Health. 2007 Jul;121(7):497-509 [17544467.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2007 Nov 9;56(44):1157-61 [17989644.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Dec;5(12):1413-7, 1417.e1-2 [17997357.001]
  • [Cites] Eur J Cancer. 2008 Feb;44(3):465-71 [18221867.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):352-8 [18268119.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7 [18695138.001]
  • [Cites] Health Care Women Int. 2008 Nov-Dec;29(10):997-1018 [18821211.001]
  • [Cites] Br J Cancer. 2008 Nov 4;99(9):1506-10 [18841152.001]
  • [Cites] Gut. 2009 Jan;58(1):16-23 [18838486.001]
  • [Cites] Br J Cancer. 2009 Feb 10;100(3):551-7 [19156150.001]
  • [Cites] Scand J Public Health. 2009 Mar;37(2):146-52 [19141546.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1174-82 [19293308.001]
  • [Cites] Prev Chronic Dis. 2009 Jul;6(3):A90 [19527591.001]
  • [Cites] Cancer Causes Control. 2009 Oct;20(8):1363-8 [19455396.001]
  • [Cites] Aust N Z J Public Health. 2000 Feb;24(1):96-9 [10777989.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):340-6 [10652424.001]
  • [Cites] Eur J Cancer. 2010 Apr;46(6):1093-100 [20188539.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Control Clin Trials. 2002 Jun;23(3):321-32 [12057883.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):860-8 [12115489.001]
  • [Cites] Am J Epidemiol. 1977 Oct;106(4):260 [910794.001]
  • [Cites] Soc Sci Med. 1994 Jul;39(1):115-22 [8066482.001]
  • [Cites] J Aging Health. 1996 Aug;8(3):359-88 [10165980.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1448-56 [9136821.001]
  • [Cites] Int J Epidemiol. 1997 Aug;26(4):860-6 [9279620.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Int J Epidemiol. 1998 Apr;27(2):199-207 [9602399.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • (PMID = 20700121.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  • [Other-IDs] NLM/ PMC2938252
  •  go-up   go-down


62. Mashimo H, Wagh MS, Goyal RK: Surveillance and screening for Barrett esophagus and adenocarcinoma. J Clin Gastroenterol; 2005 Apr;39(4 Suppl 2):S33-41
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surveillance and screening for Barrett esophagus and adenocarcinoma.
  • Current recommendations for screening and surveillance of Barrett esophagus and related lesions are based on recent guidelines by the Practice Parameters Committee of the American College of Gastroenterology.
  • There is strong rationale for vigorous initial testing to document the baseline status and identify early adenocarcinoma, and for surveillance of high-grade dysplasia.
  • Recommendations for screening and surveillance are not evidence-based and unlikely to alter national mortality from esophageal adenocarcinoma.
  • Current recommendations are limited by inconsistent endoscopic findings and sampling errors, inconsistent histologic diagnoses of Barrett esophagus and dysplasia, and our poor understanding of the natural history of various histologic lesions.
  • Effective screening programs depend on development of simple, inexpensive, and reliable methods to identify the small group of patients truly at high risk for adenocarcinoma for endoscopic screening.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Esophageal Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Esophagoscopy. Esophagus / pathology. Humans. Mass Screening / methods. Population Surveillance. Practice Guidelines as Topic. Risk Factors. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15758657.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK031092; United States / NIDDK NIH HHS / DK / DK62867
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


63. Smithers BM, Couper GC, Thomas JM, Wong D, Gotley DC, Martin I, Harvey JA, Thomson DB, Walpole ET, Watts N, Burmeister BH: Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. Dis Esophagus; 2008;21(2):151-8
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus.
  • Our aim was to determine if fluorodeoxyglucose positron emission tomography (FDG-PET) could be correlated with a pathological response in patients with esophageal adenocarcinoma receiving neoadjuvant chemotherapy and/or chemoradiation therapy.
  • Patients with resectable, histologically proven adenocarcinoma of the esophagus were entered in the study.
  • Presently an FDG-PET scan performed 3-6 weeks after neoadjuvant therapy for adenocarcinoma of the esophagus should not be used as a marker of the potential result of the treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18269651.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


64. Miyashita T, Ohta T, Fujimura T, Ninomiya I, Fushida S, Hattori T, Miwa K: Duodenal juice stimulates oesophageal stem cells to induce Barrett's oesophagus and oesophageal adenocarcinoma in rats. Oncol Rep; 2006 Jun;15(6):1469-75
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenal juice stimulates oesophageal stem cells to induce Barrett's oesophagus and oesophageal adenocarcinoma in rats.
  • the present study was performed to examine the sequential process of the development of Barrett's oesophagus (BE) and oesophageal adenocarcinoma (ADC) induced by duodeno-oesophageal reflux (DER) in rats.
  • Total gastrectomy was performed in male Wistar rats weighing approximately 250 g followed by reconstruction with oesophago-jejunostomy, which causes unavoidable DER without exposure to exogenous carcinogens.
  • On the 20th week, glandular structures that stained positively with Galactose oxidase-Schiff (foveolar metaplasia) were observed in the basal layer of the oesophageal squamous epithelium.
  • Persistent stimulation with DER can alter the stem cells in the squamous epithelial basal layer leading to the formation of columnar-lined cells and subsequent ADC.
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus / etiology. Duodenogastric Reflux / complications. Duodenum / secretion. Esophageal Neoplasms / etiology. Esophagus / pathology. Gastroesophageal Reflux / complications. Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685381.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


65. Gockel I, Sultanov FS, Domeyer M, Goenner U, Junginger T: Developments in esophageal surgery for adenocarcinoma: a comparison of two decades. BMC Cancer; 2007;7:114
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Developments in esophageal surgery for adenocarcinoma: a comparison of two decades.
  • BACKGROUND: The objective of this study was to examine outcomes in patients undergoing esophageal resection for adenocarcinoma at our institution during a 20-year period and, in particular, to address temporal trends in long-term survival.
  • METHODS: Out of 470 patients who underwent esophagectomy for malignancy between September 1985 and September 2005, a total number of 175 patients presented with esophageal adenocarcinoma.
  • Patients enrolled in this study included AEG (adenocarcinoma of the esophagogastric junction) type I tumors only.
  • RESULTS: The overall survival was significantly more favourable in patients undergoing esophageal resection for adenocarcinoma in the recent time period (DII, 10/1995 to 9/2005) as compared to the early time period (DI, 9/1985 to 9/1995) (log rank test: p = 0.0329).
  • CONCLUSION: Based on our experience, overall survival is improving over time for adenocarcinoma of the esophagus.
  • Factors that may play an important role in this trend include early diagnosis and improved patient selection through better preoperative staging, improved surgical technique with a tailored approach carefully evaluated by physiologic patient status, comorbidity and tumor extent.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Esophageal Neoplasms / mortality. Esophageal Neoplasms / surgery. Esophagectomy / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):421-40, viii [12134611.001]
  • [Cites] Ann Surg. 2002 Sep;236(3):376-84; discussion 384-5 [12192324.001]
  • [Cites] Dis Esophagus. 2002;15(2):106-8 [12220415.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1662-9 [12444180.001]
  • [Cites] Ann Surg. 2003 Sep;238(3):339-47; discussion 347-8 [14501500.001]
  • [Cites] World J Surg. 2004 Jun;28(6):520-5 [15366737.001]
  • [Cites] Thorac Surg Clin. 2004 Feb;14(1):87-94 [15382312.001]
  • [Cites] Arch Surg. 2004 Oct;139(10):1043-9 [15492140.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] World J Surg. 1996 May;20(4):507-10 discussion 511 [8662143.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 May;113(5):836-46; discussion 846-8 [9159617.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):579-83 [9635705.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] J Gastrointest Surg. 1998 Mar-Apr;2(2):186-92 [9834415.001]
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):305-13 [11208820.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):279-86 [11466680.001]
  • [Cites] Surg Oncol. 2001 Nov;10(3):103-11 [11750229.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i38-42 [15711007.001]
  • [Cites] J Clin Gastroenterol. 2005 Apr;39(4 Suppl 2):S33-41 [15758657.001]
  • [Cites] Dis Esophagus. 2005;18(1):17-20 [15773836.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):659-68 [16129366.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):12-30 [16378161.001]
  • [Cites] Future Oncol. 2006 Aug;2(4):469-76 [16922614.001]
  • (PMID = 17603896.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1914077
  •  go-up   go-down


66. Beales IL, Ogunwobi OO: Glycine-extended gastrin inhibits apoptosis in Barrett's oesophageal and oesophageal adenocarcinoma cells through JAK2/STAT3 activation. J Mol Endocrinol; 2009 Apr;42(4):305-18
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glycine-extended gastrin inhibits apoptosis in Barrett's oesophageal and oesophageal adenocarcinoma cells through JAK2/STAT3 activation.
  • Barrett's oesophagus (BO) and oesophageal adenocarcinoma (OAC) are regarded as complications of gastro-oesophageal reflux disease, although all the factors that contribute to the development of these lesions are unknown.
  • We have examined the effects of glycine-extended gastrin (G-Gly), an alternative product of progastrin processing on apoptosis in the QhERT Barrett's oesophageal cell line and OE33 and BIC-1 OAC cells.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis / drug effects. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Gastrins / pharmacology. Janus Kinase 2 / metabolism. STAT3 Transcription Factor / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19153190.001).
  • [ISSN] 1479-6813
  • [Journal-full-title] Journal of molecular endocrinology
  • [ISO-abbreviation] J. Mol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Gastrins; 0 / RNA, Small Interfering; 0 / Receptors, Cholecystokinin; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / glycine-extended gastrin 17; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


67. Lerut T, Decker G, Coosemans W, De Leyn P, Decaluwé H, Nafteux P, Van Raemdonck D: Quality indicators of surgery for adenocarcinoma of the esophagus and gastroesophageal junction. Recent Results Cancer Res; 2010;182:127-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality indicators of surgery for adenocarcinoma of the esophagus and gastroesophageal junction.
  • Surgical treatment of adenocarcinoma of the esophagus and gastroesophageal junction is complex and challenging.
  • As a result there is disagreement on the selection of patients for surgery, type of surgical approach in particular in relation to the extent of lymph node dissection as well as the extent of esophageal and/or gastric resection.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676877.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


68. Tuynman JB, Lagarde SM, Ten Kate FJ, Richel DJ, van Lanschot JJ: Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer; 2008 Mar 25;98(6):1102-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma.
  • Oesophageal adenocarcinoma is an aggressive malignancy with propensity for early lymphatic and haematogenous dissemination.
  • Tumour sections from 145 consecutive patients undergoing intentionally curative surgery for oesophageal adenocarcinoma were immunohistochemically analysed for Met and COX-2 expression.
  • These findings support the importance of Met in oesophageal adenocarcinoma and support the concept of Met tyrosine kinase inhibition as (neo-) adjuvant treatment.
  • [MeSH-major] Adenocarcinoma / metabolism. Esophageal Neoplasms / metabolism. Proto-Oncogene Proteins c-met / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2005 Dec;242(6):840-9, discussion 849-50 [16327494.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):172-87 [16014887.001]
  • [Cites] Arch Surg. 2006 May;141(5):476-81; discussion 481-2 [16702519.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):176-84 [16858179.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):637-45 [16862193.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4347-55 [16963732.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5936-43 [17062664.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6144-52 [17062691.001]
  • [Cites] Neoplasia. 2006 Nov;8(11):949-55 [17132227.001]
  • [Cites] N Engl J Med. 2006 Dec 28;355(26):2733-43 [17192538.001]
  • [Cites] Lancet. 2007 Jan 6;369(9555):29-36 [17208639.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] Histopathology. 2007 Jan;50(2):203-9 [17222248.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7345-55 [14612533.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5161-70 [14613995.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):224-9 [14710233.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4784-92 [15269153.001]
  • [Cites] Int J Oncol. 2004 Oct;25(4):831-40 [15375530.001]
  • [Cites] Am J Gastroenterol. 2001 Apr;96(4):990-6 [11316217.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3519-25 [11705871.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):8-13 [11857377.001]
  • [Cites] Gastroenterology. 2002 Jun;122(7):1800-7 [12055587.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1662-9 [12444180.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6686-94 [15475459.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Nov;52(2):81-101 [15501074.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7962-70 [15520203.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):75-84 [15720819.001]
  • [Cites] J Cell Physiol. 2006 Apr;207(1):261-70 [16331686.001]
  • (PMID = 18349821.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  • [Other-IDs] NLM/ PMC2275481
  •  go-up   go-down


69. Boult JK, Tanière P, Hallissey MT, Campbell MJ, Tselepis C: Oesophageal adenocarcinoma is associated with a deregulation in the MYC/MAX/MAD network. Br J Cancer; 2008 Jun 17;98(12):1985-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oesophageal adenocarcinoma is associated with a deregulation in the MYC/MAX/MAD network.
  • Oesophageal adenocarcinoma, which arises from an acquired columnar lesion, Barrett's metaplasia, is rising in incidence more rapidly than any other cancer in the Western world.
  • Elevated expression of c-MYC has been demonstrated in oesophageal adenocarcinoma; however, the expression of other members of the MYC/MAX/MAD network has not been addressed.
  • The aims of this work were to characterise the expression of c-MYC, MAX and the MAD family in adenocarcinoma development and assess the effects of overexpression on cellular behaviour. mRNA expression in samples of Barrett's metaplasia and oesophageal adenocarcinoma were examined by qRT-PCR.
  • Consistent with previous work expression of c-MYC was deregulated in oesophageal adenocarcinoma.
  • In conclusion, the expression patterns of c-MYC, MAX and the MAD family were shown to be deregulated in the oesophageal cancer model.
  • [MeSH-major] Adenocarcinoma / genetics. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / genetics. Esophageal Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Genes, myc. Repressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i1-5 [15711002.001]
  • [Cites] Oncogene. 1995 Jun 1;10(11):2195-205 [7784064.001]
  • [Cites] Int J Oncol. 2005 May;26(5):1369-75 [15809730.001]
  • [Cites] J Cell Biol. 2005 May 9;169(3):405-13 [15866886.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Apr 15;166(2):157-62 [16631473.001]
  • [Cites] Gut. 2006 Oct;55(10):1449-60 [16641131.001]
  • [Cites] Biomarkers. 2006 Nov-Dec;11(6):547-61 [17056474.001]
  • [Cites] Dis Esophagus. 2007;20(3):212-6 [17509117.001]
  • [Cites] Neoplasia. 2004 Sep-Oct;6(5):660-73 [15548375.001]
  • [Cites] Oncogene. 1999 Nov 18;18(48):6621-34 [10597267.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):555-66 [10666385.001]
  • [Cites] Curr Opin Genet Dev. 2000 Feb;10(1):100-5 [10679391.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1623-32 [10738221.001]
  • [Cites] Am J Respir Cell Mol Biol. 2000 Oct;23(4):560-5 [11017923.001]
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:653-99 [11031250.001]
  • [Cites] Nucleic Acids Res. 2001 Jan 15;29(2):397-406 [11139609.001]
  • [Cites] Lancet. 2000 Dec 16;356(9247):2079-85 [11145505.001]
  • [Cites] Nucleic Acids Res. 1995 May 25;23(10):1686-90 [7784172.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8488-92 [7667316.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):4800-3 [7585509.001]
  • [Cites] Nat Med. 1995 Jul;1(7):638-43 [7585143.001]
  • [Cites] EMBO J. 1995 Nov 15;14(22):5646-59 [8521822.001]
  • [Cites] Oncogene. 1995 Dec 21;11(12):2487-501 [8545105.001]
  • [Cites] Cancer Lett. 1996 Apr 19;102(1-2):73-6 [8603382.001]
  • [Cites] Br J Cancer. 1996 Jun;73(11):1347-55 [8645578.001]
  • [Cites] Curr Top Microbiol Immunol. 1997;224:149-58 [9308238.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4905-12 [9354456.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5571-8 [9407969.001]
  • [Cites] Oncogene. 1998 Feb 26;16(8):967-77 [9519870.001]
  • [Cites] Oncol Rep. 1998 Jan-Feb;5(1):213-6 [9458379.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):1-11 [9858526.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):717-26 [9927431.001]
  • [Cites] Mol Cell. 1999 May;3(5):565-77 [10360173.001]
  • [Cites] Oncogene. 1999 May 13;18(19):3004-16 [10378696.001]
  • [Cites] J Biol Chem. 1999 Oct 1;274(40):28794-802 [10497252.001]
  • [Cites] Nat Cell Biol. 2001 Jun;3(6):580-6 [11389443.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Nov;14(11):1179-86 [12439111.001]
  • [Cites] Gut. 2003 Feb;52(2):174-80 [12524396.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1A):161-5 [12680208.001]
  • [Cites] Gut. 2003 May;52(5):623-8 [12692043.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v61-118 [14684501.001]
  • [Cites] Gut. 2004 Aug;53(8):1070-4 [15247170.001]
  • [Cites] Clin Exp Rheumatol. 1990 Mar-Apr;8(2):145-50 [1692520.001]
  • [Cites] Science. 1991 Mar 8;251(4998):1211-7 [2006410.001]
  • [Cites] Oncogene. 1992 Apr;7(4):775-9 [1565473.001]
  • [Cites] J Pathol. 1992 Mar;166(3):225-33 [1381423.001]
  • [Cites] Cell. 1993 Jan 29;72(2):211-22 [8425218.001]
  • [Cites] Cell. 1993 Jan 29;72(2):223-32 [8425219.001]
  • [Cites] Oncogene. 1994 Apr;9(4):1247-52 [8134128.001]
  • [Cites] J Cell Biol. 1995 Mar;128(6):1197-208 [7896882.001]
  • [Cites] Scand J Gastroenterol. 2004 Dec;39(12):1175-9 [15742992.001]
  • (PMID = 18493233.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / MAX protein, human; 0 / MXD1 protein, human; 0 / Repressor Proteins
  • [Other-IDs] NLM/ PMC2441969
  •  go-up   go-down


70. Quera R, O'Sullivan K, Quigley EM: Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma? Endoscopy; 2006 Feb;38(2):162-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
  • BACKGROUND AND STUDY AIMS: The incidence of oesophageal adenocarcinoma has increased significantly in recent years.
  • While surveillance of people with Barrett's oesophagus, its usual precursor, has been advocated in order to detect dysplasia and early cancer in those considered to be at greatest risk, the impact of such a strategy on survival from oesophageal adenocarcinoma is unclear.
  • This study aimed to determine the effect of surveillance on mortality from oesophageal adenocarcinoma in a group of patients considered to be at high risk of developing Barrett's oesophagus and adenocarcinoma.
  • PATIENTS AND METHODS: After performing a Medline search of the literature published between 1985 and 2004 for studies on gastro-oesophageal reflux disease, Barrett's oesophagus and adenocarcinoma, we examined the impact of surveillance on mortality from oesophageal adenocarcinoma in a hypothetical sample of 100 high-risk patients (men aged over 50 with Barrett's oesophagus but without high-grade dysplasia at entry).
  • RESULTS: Four patients in this high-risk group developed adenocarcinoma during surveillance, with survival rates of 78.9% (95%CI 64.9%-88.5%) at 2 years and 78.6% (95%CI 62.8%-89.2%) at 5 years.
  • Meanwhile, between 515 and 2060 patients with Barrett's oesophagus were not detected or surveyed by this strategy and between 16 and 61 of these developed adenocarcinoma, with much lower survival rates of 37.1% (95%CI 25.4%-50.3%) at 2 years and 16.7% (95%CI 9%-28.3%) at 5 years.
  • Although surveillance in the high-risk group resulted in the long-term survival of three patients who would not otherwise have survived, this gain was dramatically offset by the 13 to 51 patients, excluded from surveillance by this strategy, who died from oesophageal adenocarcinoma.
  • CONCLUSIONS: A surveillance programme based on current concepts of risk cannot have an impact on mortality from oesophageal adenocarcinoma.
  • To be effective, it will be necessary for surveillance programmes to utilise more precise methods for the identification of those who are most at risk of progression to adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / mortality. Barrett Esophagus / epidemiology. Esophageal Neoplasms / mortality. Population Surveillance. Precancerous Conditions / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16479424.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


71. Włodarczyk J: [Barret esophagus--molecular biology]. Przegl Lek; 2008;65(2):73-6
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Barret esophagus--molecular biology].
  • Increasing incidence of adenocarcinoma of the esophagus is nowadays observed in western countries.
  • Estimation of the unique molecules may, in the future, lead to early diagnostics of pathological changes in the Barret esophagus and identification of the patient at risk from cancerogenesis.
  • The aim of this study is to explain terminology of Barret esophagus, basis of histopatology, diagnostics and to show molecules which have crucial significance in cancerogenesis.
  • [MeSH-major] Barrett Esophagus / diagnosis. Barrett Esophagus / pathology. Esophageal Neoplasms / prevention & control. Genetic Markers

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663904.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Number-of-references] 62
  •  go-up   go-down


72. Murray L, Sedo A, Scott M, McManus D, Sloan JM, Hardie LJ, Forman D, Wild CP: TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut; 2006 Oct;55(10):1390-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort.
  • BACKGROUND AND AIMS: Oesophageal adenocarcinoma frequently develops on a background of metaplastic Barrett's epithelium.
  • Incident oesophageal malignancies and high grade dysplasias were identified.
  • For each case up to five controls were matched on age, sex, and year of diagnosis.
  • Biopsies from the time of diagnosis of Barrett's epithelium were stained immunohistochemically for TP53, cyclin D1, cyclooxygenase 2 (COX-2), and beta-catenin proteins.
  • RESULTS: Twenty nine incident oesophageal malignancies and six cases of high grade dysplasia were identified.
  • The odds of diffuse or intense TP53 staining were substantially elevated in biopsies from patients who developed oesophageal adenocarcinoma compared with controls (odds ratio (OR) 11.7 (95% confidence interval (CI) 1.93, 71.4)).
  • CONCLUSIONS: Immunohistochemical detection of TP53 expression is a biomarker of malignant progression in Barrett's oesophagus but sensitivity is too low to act as a criterion to inform endoscopic surveillance strategies.
  • Additional biomarkers are required which when combined with TP53 will identify, with adequate sensitivity and specificity, Barrett's patients who are at risk of developing cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / pathology. Esophageal Neoplasms / diagnosis. Esophagus / pathology. Tumor Suppressor Protein p53 / metabolism


73. Fujita M, Fujimori T, Chiba T: [The definition of Barrett's esophagus]. Nihon Rinsho; 2005 Aug;63(8):1325-32
Genetic Alliance. consumer health - Barrett's Esophagus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The definition of Barrett's esophagus].
  • Recently, according to increasing gastroesophageal reflux disease (GERD), the patients with Barrett's esophagus (BE) are increasing.
  • Since Barrett have reported cases of esophageal ulcers surrounding by columnar epithelium, the various criteria of the BE have been proposed.
  • They proposed that BE was a chance in the esophageal epithelium of any length that can be recognized at endoscopy, and confirmed to have intestinal metaplasia by biopsy of the tubular esophagus and excludes intestinal metaplasia of the cardia.
  • Endoscopically, BE is determined, when 'gastric-appearing mucosa' or apparent 'columnar lined esophagus' is evident proximal to the esophagogastric junction.
  • Especially SCE is distinctive features of BE, available for diagnosis.
  • On the other hand, BE is premalignant condition for the adenocarcinoma of the esophagus, therefore the features of the BE are researched to prevent and find out earlier development of adenocarcinoma.
  • [MeSH-major] Barrett Esophagus
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / prevention & control. Esophageal Neoplasms / etiology. Esophageal Neoplasms / prevention & control. Esophagoscopy. Gastroesophageal Reflux / complications. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101217.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 21
  •  go-up   go-down


74. Brown LM, Devesa SS, Chow WH: Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst; 2008 Aug 20;100(16):1184-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age.
  • Rapid increases in the incidence of adenocarcinoma of the esophagus have been reported among white men.
  • We identified 22,759 patients from January 1, 1975, through December 31, 2004, with esophageal cancer, of whom 9526 were diagnosed with adenocarcinoma of the esophagus.
  • Among white men, increases in the incidence of esophageal cancer were largely attributed to a 463% increase in the incidence of adenocarcinoma over this time period, from 1.01 per 100,000 person-years (95% confidence interval [CI] = 0.90 to 1.13) in 1975-1979 to 5.69 per 100,000 person-years (95% CI = 5.47 to 5.91) in 2000-2004.
  • A similar rapid increase was also apparent among white women, among whom the adenocarcinoma rate increased 335%, from 0.17 (95% CI = 0.13 to 0.21) to 0.74 per 100,000 person-years (95% CI = 0.67 to 0.81), over the same time period.
  • Adenocarcinoma rates rose among white men and women in all stage and age groups, indicating that these increases are real and not an artifact of surveillance.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Epidemiol Rev. 2001;23(1):3-13 [11588851.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):101-7 [12672038.001]
  • [Cites] J Natl Cancer Inst. 1989 Oct 18;81(20):1568-71 [2795682.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] JAMA. 1993 Sep 15;270(11):1320 [8360967.001]
  • [Cites] Am J Epidemiol. 1995 Feb 15;141(4):300-4 [7840107.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] J Infect Dis. 2005 Mar 1;191(5):761-7 [15688293.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):872-8 [16702363.001]
  • [Cites] Cancer Causes Control. 2006 Sep;17(7):971-81 [16841264.001]
  • [Cites] Scand J Gastroenterol. 2007 Jan;42(1):17-22 [17190757.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):352-8 [18268119.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Gut. 2008 Jun;57(6):727-33 [17895354.001]
  • [CommentIn] J Natl Cancer Inst. 2009 Oct 21;101(20):1428; author reply 1429 [19724025.001]
  • (PMID = 18695138.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS53143; NLM/ PMC2518165
  •  go-up   go-down


75. Sarbia M: The histological appearance of oesophageal adenocarcinoma--an analysis based on 215 resection specimens. Virchows Arch; 2006 May;448(5):532-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The histological appearance of oesophageal adenocarcinoma--an analysis based on 215 resection specimens.
  • The current study was performed to determine whether the histopathological appearance of oesophageal adenocarcinoma (AC) differs significantly from that of cardiac or gastric AC.
  • Therefore, HE-stained slides of 215 primarily resected oesophageal AC, 108 cardiac and 184 gastric AC were classified according to a variety of clinico-pathologic parameters.
  • According to Lauren's classification, oesophageal AC (1.4%) less frequently belonged to the diffuse type than cardiac (2.8%) and gastric AC (23.9%; p<0.0001).
  • Tubular and papillary AC, as defined by the WHO classification, were more frequent among oesophageal (94.4%) than among cardiac (87.0%) and gastric AC (59.2%; p<0.0001).
  • Solid carcinomas, according to Carneiro's classification, were less frequent among oesophageal (2.8%) than among cardiac (10.2%) and gastric AC (9.2%; p<0.0001).
  • Oesophageal AC were graded more frequently G1/G2 (53.9%) than cardiac (30.6%) and gastric AC (27.7%; p<0.0001).
  • Among oesophageal AC, Lauren's classification (p=0.0067), Carneiro's classification (p=0.0170), tumour grade (p=0.0005), lymphatic vessel invasion (p<0.0001) but not WHO classification were histological predictors of postoperative survival.
  • In conclusion, oesophageal AC displays the same histological spectrum as cardiac and gastric AC.
  • However, the relative proportion of differentiated, gland-forming carcinomas is significantly more frequent in the oesophagus than in the cardia and in the stomach.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Esophageal Neoplasms / classification. Esophageal Neoplasms / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1984 Mar;86(3):461-7 [6693012.001]
  • [Cites] Hum Pathol. 1986 May;17(5):482-7 [3699811.001]
  • [Cites] Gastrointest Endosc. 2004 Nov;60(5):703-10 [15557945.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1213-21 [12218578.001]
  • [Cites] Surgery. 2001 Jan;129(1):103-9 [11150040.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):444-9 [15297937.001]
  • [Cites] Int J Cancer. 2004 Aug 20;111(2):224-8 [15197775.001]
  • [Cites] Int J Cancer. 1995 May 4;61(3):333-6 [7729944.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;120(1-2):95-9 [8270616.001]
  • [Cites] Virchows Arch. 2000 Oct;437(4):348-50 [11097357.001]
  • [Cites] Am J Surg. 1985 Sep;150(3):365-9 [4037198.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Am J Surg Pathol. 1995 Feb;19(2):183-91 [7832278.001]
  • [Cites] World J Surg. 2003 Sep;27(9):1040-6 [12917759.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):33-40 [11141476.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2003 Jul;13(3):505-12 [14629106.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2429-37 [10861416.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 2002 Mar 14;346(11):836-42 [11893796.001]
  • [Cites] Gut. 2002 Nov;51(5):671-6 [12377805.001]
  • [Cites] Pathol Res Pract. 1995 Jul;191(6):571-84 [7479380.001]
  • (PMID = 16498532.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


76. Kutup A, Yekebas EF, Izbicki JR: Current diagnosis and future impact of micrometastases for therapeutic strategies in adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res; 2010;182:115-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current diagnosis and future impact of micrometastases for therapeutic strategies in adenocarcinoma of the esophagus, gastric cardia, and upper gastric third.
  • Esophageal and gastric cancers are aggressive neoplasms with a poor prognosis.
  • The potential role and -benefit of an antibody-based treatment as a therapeutic target would be of particular interest in tumors with a notoriously poor prognosis such as esophageal cancer and cardia cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Esophageal Neoplasms / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676876.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


77. van Lier MG, Bomhof FJ, Leendertse I, Flens M, Balk AT, Loffeld RJ: Cytokeratin phenotyping does not help in distinguishing oesophageal adenocarcinoma from cancer of the gastric cardia. J Clin Pathol; 2005 Jul;58(7):722-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin phenotyping does not help in distinguishing oesophageal adenocarcinoma from cancer of the gastric cardia.
  • BACKGROUND: It is sometimes difficult to distinguish between cardia cancer and oesophageal cancer.
  • METHODS: Consecutive patients with a malignant tumour in the oesophagus or stomach were recruited.
  • RESULTS: Endoscopically located adenocarcinoma of the oesophagus was present in 84 patients (64 men, 20 women; mean age, 68 years; range, 44-91).
  • Cancer located primarily in the gastric cardia was present in 63 patients (42 men, 21 women; mean age, 68 years; range, 42-88).
  • The histological diagnosis was metastasis from a primary tumour outside the oesophagus or stomach in 19 patients.
  • Patients in group A had definite oesophageal cancer, group B patients had a definite carcinoma located in the gastric cardia, and group C patients had an obstructing tumour distal in the oesophagus at the level of the diaphragm, which could not be passed with the endoscope.
  • CONCLUSION: CK phenotyping cannot distinguish between cancer arising from a Barrett's oesophagus and carcinoma originating in the gastric cardia.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cardia. Esophageal Neoplasms / diagnosis. Keratins / metabolism. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adult. Aged. Aged, 80 and over. Barrett Esophagus / diagnosis. Barrett Esophagus / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Proteins / metabolism. Precancerous Conditions / diagnosis. Precancerous Conditions / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2001 Apr;38(4):307-11 [11318895.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):288-94 [10088547.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):445-54 [11962749.001]
  • [Cites] Mod Pathol. 2002 Jun;15(6):611-6 [12065774.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1213-21 [12218578.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2514-23 [12385432.001]
  • [Cites] Neth J Med. 2003 Jan;61(1):14-8 [12688564.001]
  • [Cites] Histopathology. 2003 Aug;43(2):127-34 [12877727.001]
  • [Cites] Pathol Res Pract. 2003;199(9):581-7 [14621193.001]
  • [Cites] Histopathology. 2003 Nov;43(5):453-61 [14636271.001]
  • [Cites] Hum Pathol. 2004 Mar;35(3):371-6 [15017595.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):402-7 [8509215.001]
  • [Cites] JAMA. 1993 Sep 15;270(11):1320 [8360967.001]
  • [Cites] Gastroenterol Clin North Am. 1997 Sep;26(3):487-94 [9309399.001]
  • [Cites] Lancet. 1997 Sep 27;350(9082):933 [9314878.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):820-31 [11857318.001]
  • (PMID = 15976339.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC1770716
  •  go-up   go-down


78. Van Blankenstein M, Looman CW, Kruijshaar ME, Siersema PD, Kuipers EJ, Bytzer P: Modelling a population with Barrett's oesophagus from oesophageal adenocarcinoma incidence data. Scand J Gastroenterol; 2007 Mar;42(3):308-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modelling a population with Barrett's oesophagus from oesophageal adenocarcinoma incidence data.
  • OBJECTIVE: A recent study of adenocarcinoma of the oesophagus (ACO) incidence rates in Denmark showed a steep fall in the over-80 population, interpreted as the result of a decline in the prevalence of Barrett's oesophagus (BO) in this age group, for which three hypotheses were advanced: the specific mortality from ACO and, superimposed, either excess mortality from causes of death unrelated to ACO or a birth cohort effect.
  • [MeSH-major] Adenocarcinoma / epidemiology. Barrett Esophagus / epidemiology. Esophageal Neoplasms / epidemiology. Models, Statistical

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17354109.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


79. Lukić M, Segec A, Segeca I, Pinotić L, Pinotić K, Atalić B, Solić K, Vcev A: The role of the nutrition in the pathogenesis of gastroesophageal reflux disease, Barrett's oesophagus and oesophageal adenocarcinoma. Coll Antropol; 2010 Sep;34(3):905-9
MedlinePlus Health Information. consumer health - Nutrition for Seniors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of the nutrition in the pathogenesis of gastroesophageal reflux disease, Barrett's oesophagus and oesophageal adenocarcinoma.
  • This paper aims at evaluating the role of improper nutrition in the pathogenesis of gastroesophageal reflux disease (GERD), Barrett's oesophagus (BE), and oesophageal adenocarcinoma (EADC).
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus / etiology. Esophageal Neoplasms / etiology. Gastroesophageal Reflux / etiology. Nutritional Physiological Phenomena


80. Onwuegbusi BA, Rees JR, Lao-Sirieix P, Fitzgerald RC: Selective loss of TGFbeta Smad-dependent signalling prevents cell cycle arrest and promotes invasion in oesophageal adenocarcinoma cell lines. PLoS One; 2007 Jan 31;2(1):e177
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective loss of TGFbeta Smad-dependent signalling prevents cell cycle arrest and promotes invasion in oesophageal adenocarcinoma cell lines.
  • In cancer, Transforming Growth Factor beta (TGFbeta) increases proliferation and promotes invasion via selective loss of signalling pathways.
  • Oesophageal adenocarcinoma arises from Barrett's oesophagus, progresses rapidly and is usually fatal.
  • We therefore investigated the role of TGFbeta in Barrett's associated oesophageal adenocarcinoma using a panel of cell lines (OE33, TE7, SEG, BIC, FLO).
  • 4/5 adenocarcinoma cell lines failed to cell cycle arrest, down-regulate c-Myc or induce p21 in response to TGFbeta, and modulation of a Smad3/4 specific promoter was inhibited.
  • These hyperproliferative adenocarcinoma cell lines displayed a TGFbeta induced increase in the expression of the extracellular matrix degrading proteinases, urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1), which correlated with an invasive cell phenotype as measured by in vitro migration, invasion and cell scattering assays.
  • These data would support a dual role for TGFbeta in oesophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Esophageal Neoplasms / metabolism. Esophageal Neoplasms / pathology. Signal Transduction / physiology. Smad3 Protein / metabolism. Transforming Growth Factor beta / metabolism
  • [MeSH-minor] Barrett Esophagus / complications. Cell Cycle / physiology. Cell Line, Tumor. Cell Proliferation. Enzyme Activation. Enzyme Inhibitors / metabolism. Extracellular Matrix / metabolism. Extracellular Signal-Regulated MAP Kinases / genetics. Extracellular Signal-Regulated MAP Kinases / metabolism. Gene Expression Regulation. Humans. JNK Mitogen-Activated Protein Kinases / genetics. JNK Mitogen-Activated Protein Kinases / metabolism. Neoplasm Invasiveness. Phosphatidylinositol 3-Kinases / genetics. Phosphatidylinositol 3-Kinases / metabolism. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Physiol. 2000 Feb;182(2):269-80 [10623891.001]
  • [Cites] Gut. 2006 Jun;55(6):764-74 [16368780.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):400-8 [11283614.001]
  • [Cites] Ann Surg. 2001 Aug;234(2):172-80 [11505062.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S44-51 [11684442.001]
  • [Cites] J Cell Sci. 2001 Nov;114(Pt 21):3905-14 [11719557.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):237-46 [11786417.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3150-7 [11689575.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):314-46 [11839647.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):207-10 [12023852.001]
  • [Cites] EMBO J. 2002 Jul 15;21(14):3749-59 [12110587.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):391-401 [12538493.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):5941-6 [12493778.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] Oncogene. 2004 Aug 5;23(35):5978-85 [15184866.001]
  • [Cites] Surgery. 2004 Aug;136(2):310-6 [15300196.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Apr;83(8):2438-42 [2871553.001]
  • [Cites] J Biol Chem. 1991 Jan 15;266(2):1092-100 [1985937.001]
  • [Cites] Oncogene. 1991 Sep;6(9):1583-92 [1923525.001]
  • [Cites] J Biol Chem. 1991 Dec 5;266(34):23048-52 [1744101.001]
  • [Cites] J Biol Chem. 1992 Mar 15;267(8):5029-31 [1544886.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1785-94 [7907940.001]
  • [Cites] J Biol Chem. 1995 Mar 31;270(13):7117-24 [7706248.001]
  • [Cites] J Biol Chem. 1995 Sep 29;270(39):23007-12 [7559439.001]
  • [Cites] Br J Surg. 1996 Aug;83(8):1152-5 [8869332.001]
  • [Cites] Eur J Biochem. 1996 Oct 15;241(2):393-402 [8917435.001]
  • [Cites] Int J Cancer. 1997 Jul 3;72(1):1-22 [9212216.001]
  • [Cites] Genes Dev. 1997 Dec 1;11(23):3157-67 [9389648.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):135-44 [9422531.001]
  • [Cites] Int J Cancer. 1998 Mar 2;75(5):721-30 [9495240.001]
  • [Cites] Nat Med. 1998 Aug;4(8):923-8 [9701244.001]
  • [Cites] Nature. 1998 Aug 27;394(6696):909-13 [9732876.001]
  • [Cites] Clin Exp Metastasis. 1999 Feb;17(1):77-85 [10390151.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4782-8 [15930298.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):407-15 [10652434.001]
  • (PMID = 17264880.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105365007
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Smad3 Protein; 0 / Transforming Growth Factor beta; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC1766472
  • [General-notes] NLM/ Original DateCompleted: 20070723
  •  go-up   go-down


81. Lawal A, Antonik S, Dua K, Massey BT: Esophageal adenocarcinoma: pseudo-nutcracker esophagus. Dysphagia; 2009 Jun;24(2):234-7
MedlinePlus Health Information. consumer health - Swallowing Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal adenocarcinoma: pseudo-nutcracker esophagus.
  • Pseudoachalasia due to adenocarcinoma is well known.
  • We report a case of nutcracker esophagus in the setting of outflow obstruction from esophageal adenocarcinoma.
  • Endoscopy is warranted to exclude similar lesions in patients with "pseudo-nutcracker esophagus".
  • [MeSH-major] Deglutition. Deglutition Disorders / etiology. Esophageal Neoplasms / surgery. Esophagectomy
  • [MeSH-minor] Esophageal Achalasia / diagnosis. Esophageal Achalasia / surgery. Female. Humans. Jejunostomy. Manometry. Middle Aged

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Gastroenterol Hepatol. 1999 Dec;11(12):1349-54 [10654793.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1371-7 [11374670.001]
  • [Cites] Ann Intern Med. 1987 Apr;106(4):593-7 [3826958.001]
  • [Cites] Am J Gastroenterol. 1994 Nov;89(11):2014-8 [7942729.001]
  • [Cites] Ann Surg. 2006 Nov;244(5):723-33 [17060765.001]
  • [Cites] AJR Am J Roentgenol. 1986 Oct;147(4):692-5 [3489366.001]
  • [Cites] Ann Intern Med. 1978 Sep;89(3):315-8 [686541.001]
  • [Cites] Gastrointest Endosc. 1997 Sep;46(3):223-5 [9378208.001]
  • [Cites] Can J Gastroenterol. 2006 May;20(5):335-7 [16691299.001]
  • [Cites] Scand J Gastroenterol. 2005 Apr;40(4):378-85 [16028431.001]
  • [Cites] Am J Physiol. 1990 Feb;258(2 Pt 1):G208-15 [2305886.001]
  • [Cites] J Clin Gastroenterol. 1991 Oct;13(5):554-8 [1744393.001]
  • [Cites] Am J Gastroenterol. 1998 Jan;93(1):103-5 [9448185.001]
  • (PMID = 18626696.001).
  • [ISSN] 1432-0460
  • [Journal-full-title] Dysphagia
  • [ISO-abbreviation] Dysphagia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Loaeza-del Castillo A, Villalobos-Pérez JJ: [Study of 30 years on the change in the frequency of esophageal squamous cell carcinoma, esophageal adenocarcinoma and adenocarcinoma of the esophagogastric union]. Rev Gastroenterol Mex; 2008 Jan-Mar;73(1):11-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of 30 years on the change in the frequency of esophageal squamous cell carcinoma, esophageal adenocarcinoma and adenocarcinoma of the esophagogastric union].
  • [Transliterated title] Estudio de 30 años sobre el cambio en la frecuencia de carcinoma epidermoide esofágico, adenocarcinoma esofágico y adenocarcinoma de la unión esofagogástrica.
  • Esophageal cancer mortality is high and the incidence of this neoplasm is increasing.
  • OBJECTIVE: Our aim was to compare the frequency of esophageal adenocarcinoma cases (EA) and squamous cell carcinoma (SCC) cases in two study periods (1977-1988 vs. 1989-2006).
  • METHOD: Patients with esophageal cancer or adenocarcinoma of gastroesophageal junction (AGEJ) referred to the Nation al Institute of Medical Sciences and Nutrition "Salvador Zubirán" during 1989-2006 were included.
  • Risk factors for esophageal cancer and AGEJ were investigated.
  • The association between Barrett's esophagus and EA (OR 14; CI 95% 1.65-119.2, P = 0.0035) and for GEJC (RM 13.6; IC 95% 1.6-116, P = 0.004) was significant.
  • CONCLUSION: There has been an increase in EA, being now the predominant hystologic type of esophageal cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Esophageal Neoplasms / epidemiology. Esophagogastric Junction

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18792668.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


83. Li H, Zhang L, Lou H, Ding I, Kim S, Wang L, Huang J, Di Sant'Agnese PA, Lei JY: Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus. Am J Clin Pathol; 2005 Aug;124(2):282-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus.
  • Overexpression of decoy receptor (DcR) 3 protein, a recently discovered member of the tumor necrosis factor receptor superfamily, was examined in 40 esophagogastrectomy specimens containing areas of Barrett esophagus (n = 27), low-grade dysplasia (n = 27), high-grade dysplasia or carcinoma in situ (n = 22), and esophageal adenocarcinoma (EAC; n = 28) with immunohistochemical analysis.
  • The results revealed significantly more overexpression of DcR3 in high-grade dysplasia or carcinoma in situ and EAC than in benign esophageal mucosa (both P < .0001), Barrett esophagus (both P < .001), and low-grade dysplasia (P < .01 and P = .033, respectively).
  • Low-grade dysplasia also showed significant overexpression of DcR3 compared with benign esophagus (P < .05) but not with Barrett esophagus (P > .05).
  • Our results suggest that overexpression of DcR3 protein might aid in the diagnosis of high-grade dysplasia or carcinoma in situ and EAC and also might serve as a potential therapeutic target.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. Esophageal Neoplasms / metabolism. Membrane Glycoproteins / biosynthesis. Precancerous Conditions / metabolism. Receptors, Cell Surface / biosynthesis. Receptors, Tumor Necrosis Factor / biosynthesis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16040301.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / Receptors, Cell Surface; 0 / Receptors, Tumor Necrosis Factor; 0 / Receptors, Tumor Necrosis Factor, Member 6b; 0 / TNFRSF6B protein, human
  •  go-up   go-down


84. Song S, Guha S, Liu K, Buttar NS, Bresalier RS: COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma. Gut; 2007 Nov;56(11):1512-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma.
  • OBJECTIVES: Bile reflux contributes to oesophageal injury and neoplasia.
  • COX-2 is involved in both inflammation and carcinogenesis; however, the precise mechanisms by which bile acids promote COX-2 expression in the oesophagus are largely unknown.
  • We analysed the molecular mechanisms that govern bile acid-mediated expression of COX-2 in Barrett's oesophagus and oesophageal adenocarcinoma (OA).
  • DESIGN: The effects of bile acids on COX-2 expression were analysed in immortalised Barrett's oesophagus and OA cells using immunoblotting and transient transfections.
  • Immunohistochemistry was performed on oesophageal mucosa obtained from an established rat model of bile reflux.
  • CONCLUSIONS: Unconjugated bile acids induce CREB and AP-1-dependent COX-2 expression in Barrett's oesophagus and OA through ROS-mediated activation of PI3K/AKT and ERK1/2.
  • This study enhances our understanding of the molecular mechanisms by which bile acids promote the development of oesophageal adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2001 Dec;121(6):1286-93 [11729107.001]
  • [Cites] J Biol Chem. 2001 Jan 5;276(1):413-20 [11020383.001]
  • [Cites] Carcinogenesis. 2002 Jan;23(1):73-9 [11756226.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):299-307 [11832445.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):985-93 [11910351.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):18649-57 [11901151.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Aug;283(2):G327-34 [12121879.001]
  • [Cites] Mol Cell Biol. 2003 May;23(9):3052-66 [12697808.001]
  • [Cites] Laryngoscope. 2003 Jun;113(6):1059-63 [12782823.001]
  • [Cites] Carcinogenesis. 2003 Jul;24(7):1183-90 [12807723.001]
  • [Cites] Nutr Cancer. 2003;46(1):82-92 [12925308.001]
  • [Cites] Gut. 2003 Dec;52(12):1678-83 [14633942.001]
  • [Cites] Gut. 2004 Jan;53(1):27-33 [14684572.001]
  • [Cites] Carcinogenesis. 2004 Mar;25(3):419-23 [14656949.001]
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):265-70 [15101710.001]
  • [Cites] Mol Biol Cell. 2004 May;15(5):2156-63 [15004225.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):57-67 [15213619.001]
  • [Cites] J Immunol. 2004 Aug 1;173(3):2011-22 [15265936.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Oct;287(4):G743-8 [15231484.001]
  • [Cites] Hepatology. 2004 Oct;40(4):961-71 [15382121.001]
  • [Cites] Endoscopy. 1979 May;11(2):121-6 [446424.001]
  • [Cites] J Clin Invest. 1986 Mar;77(3):850-9 [3005368.001]
  • [Cites] J Clin Invest. 1987 Feb;79(2):532-41 [3027128.001]
  • [Cites] Br J Surg. 1988 Jun;75(6):540-3 [3395818.001]
  • [Cites] Oncogene. 1994 Mar;9(3):791-9 [8108121.001]
  • [Cites] Eur J Biochem. 1994 May 1;221(3):889-97 [8181472.001]
  • [Cites] Carcinogenesis. 1994 Sep;15(9):1911-5 [7923585.001]
  • [Cites] Carcinogenesis. 1996 Mar;17(3):427-33 [8631127.001]
  • [Cites] Am J Gastroenterol. 2001 Apr;96(4):990-6 [11316217.001]
  • [Cites] Mutat Res. 2001 Sep 1;480-481:359-69 [11506828.001]
  • [Cites] Cell Growth Differ. 1997 Mar;8(3):283-91 [9056670.001]
  • [Cites] J Biol Chem. 1998 Jan 23;273(4):2424-8 [9442092.001]
  • [Cites] Gastroenterology. 1998 Feb;114(2):295-304 [9453489.001]
  • [Cites] J Gastrointest Surg. 1998 May-Jun;2(3):260-8 [9841983.001]
  • [Cites] J Gastrointest Surg. 1998 Jul-Aug;2(4):333-41 [9841990.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):595-603 [10027336.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Gut. 1999 May;44(5):598-602 [10205192.001]
  • [Cites] Food Chem Toxicol. 2005 Jan;43(1):87-93 [15582199.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):63-8 [15621992.001]
  • [Cites] Mutat Res. 2005 Jan;589(1):47-65 [15652226.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3462-9 [15833882.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):351-62 [15837624.001]
  • [Cites] J Biol Chem. 2005 Jun 3;280(22):21237-45 [15767259.001]
  • [Cites] J Gastroenterol. 2005 Jul;40(7):690-7 [16082585.001]
  • [Cites] Free Radic Biol Med. 2005 Sep 15;39(6):769-80 [16109307.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2004 Dec;1(2):106-12 [16265072.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Dec;289(6):G991-7 [16081761.001]
  • [Cites] Mol Biol Cell. 2005 Dec;16(12):5579-91 [16195339.001]
  • [Cites] Oncogene. 2005 Dec 15;24(56):8268-76 [16170369.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Feb;290(2):G335-42 [16239404.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):287-96 [16353199.001]
  • [Cites] Gut. 2006 Apr;55(4):450-6 [16210398.001]
  • [Cites] Oncogene. 2006 Apr 6;25(15):2170-80 [16301994.001]
  • [Cites] Cell Signal. 2006 Aug;18(8):1101-7 [16516442.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):771-82 [16557574.001]
  • [Cites] Gastroenterology. 2000 Mar;118(3):487-96 [10702199.001]
  • [Cites] J Biol Chem. 2000 May 19;275(20):15090-8 [10748108.001]
  • [Cites] J Gastrointest Surg. 2000 Mar-Apr;4(2):124-8 [10885957.001]
  • [Cites] Gastroenterology. 2001 Dec;121(6):1391-9 [11729118.001]
  • (PMID = 17604323.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA069480; United States / NCI NIH HHS / CA / R01CA69480
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / Reactive Oxygen Species; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.3.1.48 / CREB-Binding Protein; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  • [Other-IDs] NLM/ PMC2095641
  •  go-up   go-down


85. Shaheen NJ: Advances in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology; 2005 May;128(6):1554-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in Barrett's esophagus and esophageal adenocarcinoma.
  • Despite advances in diagnosis and therapy, esophageal adenocarcinoma remains an aggressive and usually lethal tumor.
  • This review focuses on the epidemiology of esophageal adenocarcinoma and its presumed precursor lesion, Barrett's esophagus; the pathogenesis of the cancer; advances in treatment of adenocarcinoma and Barrett's esophagus; and strategies for cancer prevention.
  • Although the absolute number of cases of adenocarcinoma in the United States is still small, the incidence of this cancer has increased dramatically in the last 40 years, and adenocarcinoma is now the predominant form of esophageal cancer in this country.
  • Recent evidence suggests that Barrett's esophagus is more prevalent in asymptomatic individuals than previously appreciated.
  • The pathogenesis of Barrett's esophagus is poorly understood.
  • Given that some subjects will have repeated bouts of severe erosive esophagitis and never develop Barrett's esophagus, host factors must play an important role.
  • The utility of neoadjuvant radiation and chemotherapy in those with adenocarcinoma, although they are widely practiced, is not of clear benefit, and some authorities recommend against it.
  • Ablative therapies, as well as endoscopic mucosal resection, hold promise for those with superficial cancer or high-grade dysplasia.
  • The value of chemoprevention in subjects with dysplastic Barrett's esophagus by use of cyclooxygenase 2 inhibitors, nonsteroidal anti-inflammatory drugs, or proton pump inhibitors is unknown.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Barrett Esophagus / pathology. Barrett Esophagus / therapy. Esophageal Neoplasms / pathology. Esophageal Neoplasms / therapy

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15887151.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K23DK59311-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 130
  •  go-up   go-down


86. Montgomery E, Mamelak AJ, Gibson M, Maitra A, Sheikh S, Amr SS, Yang S, Brock M, Forastiere A, Zhang S, Murphy KM, Berg KD: Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions. Appl Immunohistochem Mol Morphol; 2006 Mar;14(1):24-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions.
  • The authors identified upregulation of Claudins 3, 4, and 7 in gastric adenocarcinoma using Affymetrix U-133 oligonucleotide microarrays and immunohistochemistry (IHC).
  • The authors hypothesized that Claudins would be similarly overexpressed in Barrett's esophagus (BE)/adenocarcinoma.
  • Claudins 3, 4, and 7 gene expression was analyzed by Affymetrix U-133 microarrays in three esophageal adenocarcinomas, one case of BE, and three normal esophagi.
  • IHC validation was performed using tissue microarrays constructed from esophageal resection specimens containing squamous (44 cases), gastric (40 cases), and non-dysplastic BE (16 cases), low-grade and high-grade dysplasia (16 and 26 cases), adenocarcinoma (58 cases), and nodal metastases (27 cases).
  • By microarray analysis, Claudin 3 showed a marked increase in mRNA expression compared with normal esophagus (approximately 100-fold).
  • By IHC, Claudin 3 expression was 1+ in most (>95%) normal squamous or gastric tissues and 2+ to 4+ in more than 80% of high-grade dysplasia, adenocarcinoma, and metastases specimens.
  • Claudin 4 protein expression was 2+ or less in most squamous and gastric mucosa (>90%) but 3+ or 4+ in BE, low- and high-grade dysplasia, adenocarcinoma, and metastases specimens (>90%).
  • In high-grade dysplasia, adenocarcinoma, and metastases, Claudin 7 was less intense, with 60% to 70% staining 3+ or 4+ and 30% to 40% staining weakly (1+ or 2+).
  • The findings suggest that alterations in Claudin proteins are an early event in tumorigenesis and may provide targets for diagnosis and directed therapy for esophageal adenocarcinoma and its precursors.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540726.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / CLDN7 protein, human; 0 / Claudin-3; 0 / Claudin-4; 0 / Claudins; 0 / Membrane Proteins; 0 / RNA, Messenger
  •  go-up   go-down


87. Sendler A: Metabolic response evaluation by PET during neoadjuvant treatment for adenocarcinoma of the esophagus and esophagogastric junction. Recent Results Cancer Res; 2010;182:167-77
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic response evaluation by PET during neoadjuvant treatment for adenocarcinoma of the esophagus and esophagogastric junction.
  • Following several randomized trials, neoadjuvant therapy in adenocarcinoma of esophagus and the esophagogastric junction can be seen as an international standard.
  • So far, FDG-PET does not change treatment in esophageal and gastric cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Esophageal Neoplasms / metabolism. Esophagogastric Junction / radionuclide imaging. Fluorodeoxyglucose F18. Neoadjuvant Therapy. Positron-Emission Tomography / methods. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676880.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


88. Sayana H, Wani S, Sharma P: Esophageal adenocarcinoma and Barrett's esophagus. Minerva Gastroenterol Dietol; 2007 Jun;53(2):157-69
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal adenocarcinoma and Barrett's esophagus.
  • Esophageal adenocarcinoma (EAC) is the most rapidly rising incidence cancer associated with a poor 5-year survival rate.
  • Barrett's esophagus (BE) is a well established premalignant condition for the development of EAC and hence it is imperative that patients with BE or at risk for developing BE should be identified and managed appropriately.
  • Although controversial, clinical strategies of screening and surveillance have focused on identification of esophageal neoplasia at an early asymptomatic and curable stage with the ultimate goal of preventing deaths from this cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / etiology. Barrett Esophagus / complications. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / etiology
  • [MeSH-minor] Diagnosis, Differential. Esophagectomy. Esophagoscopy. Humans. Incidence. Mass Screening. Neoplasm Staging. Population Surveillance / methods. Prevalence. Risk Factors. United States / epidemiology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17557044.001).
  • [ISSN] 1121-421X
  • [Journal-full-title] Minerva gastroenterologica e dietologica
  • [ISO-abbreviation] Minerva Gastroenterol Dietol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 95
  •  go-up   go-down


89. Hong J, Behar J, Wands J, Resnick M, Wang LJ, DeLellis RA, Lambeth D, Souza RF, Spechler SJ, Cao W: Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. Gut; 2010 Feb;59(2):170-80
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma.
  • BACKGROUND AND AIMS: Mechanisms of the progression from Barrett's oesophagus to oesophageal adenocarcinoma (OA) are not fully understood.
  • TGR5 mRNA and protein levels were significantly higher in OA tissues than in normal oesophageal mucosa or Barrett's mucosa.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Cancer. 2009;9:190 [19534809.001]
  • [Cites] BMC Cancer. 2008;8:333 [19014523.001]
  • [Cites] Gene. 2001 May 16;269(1-2):131-40 [11376945.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Aug;15(8):1087-100 [11472311.001]
  • [Cites] Am J Gastroenterol. 2002 Jan;97(1):22-6 [11808965.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):299-307 [11832445.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Jun;282(6):C1212-24 [11997235.001]
  • [Cites] Gastroenterology. 2002 Jun;122(7):1800-7 [12055587.001]
  • [Cites] Dis Esophagus. 2002;15(1):5-9 [12060036.001]
  • [Cites] Cell Mol Life Sci. 2002 Sep;59(9):1428-59 [12440767.001]
  • [Cites] Gut. 2003 Feb;52(2):174-80 [12524396.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2003 Feb;36(2):172-4 [12548050.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9435-40 [12524422.001]
  • [Cites] Gut. 2003 Jun;52(6):775-83 [12740330.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Jul;285(1):G86-95 [12799309.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Aug;285(2):C353-69 [12686516.001]
  • [Cites] Arch Biochem Biophys. 2003 Sep 1;417(1):3-11 [12921773.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Dec;126(6):1952-7 [14688711.001]
  • [Cites] Surgery. 2004 Feb;135(2):215-21 [14739857.001]
  • [Cites] Nat Rev Immunol. 2004 Mar;4(3):181-9 [15039755.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):1877-83 [15447744.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Oct;20 Suppl 5:71-80; discussion 95-6 [15456468.001]
  • [Cites] Surgery. 1992 May;111(5):503-10 [1598670.001]
  • [Cites] Ann Surg Oncol. 1994 May;1(3):252-61 [7842295.001]
  • [Cites] Gut. 1995 Aug;37(2):168-73 [7557561.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):358-70; discussion 370-1 [8813264.001]
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):2120-8 [8903332.001]
  • [Cites] Dis Esophagus. 1997 Jan;10(1):29-32; discussion 33 [9079270.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5571-8 [9407969.001]
  • [Cites] Gastroenterology. 1998 Oct;115(4):919-28 [9753495.001]
  • [Cites] J Gastrointest Surg. 1998 May-Jun;2(3):260-8 [9841983.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Gut. 1999 May;44(5):598-602 [10205192.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):327-35 [10419913.001]
  • [Cites] Nature. 1999 Sep 2;401(6748):79-82 [10485709.001]
  • [Cites] Dig Dis Sci. 2004 Oct;49(10):1664-71 [15573924.001]
  • [Cites] Mutat Res. 2005 Jan;589(1):47-65 [15652226.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i21-6 [15711004.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Apr 1;329(1):386-90 [15721318.001]
  • [Cites] Thorac Surg Clin. 2005 Aug;15(3):335-40 [16104124.001]
  • [Cites] Nature. 2006 Jan 26;439(7075):484-9 [16400329.001]
  • [Cites] EMBO J. 2006 Apr 5;25(7):1419-25 [16541101.001]
  • [Cites] J Biol Chem. 2006 Jul 21;281(29):20368-82 [16707484.001]
  • [Cites] Carcinogenesis. 2007 Jan;28(1):136-42 [16905748.001]
  • [Cites] Dis Esophagus. 2007;20(3):256-64 [17509124.001]
  • [Cites] J Biol Chem. 2007 Jun 1;282(22):16244-55 [17403674.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Sep 14;361(1):156-61 [17659258.001]
  • [Cites] Lab Invest. 2008 Jun;88(6):643-51 [18427553.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jul 18;372(1):78-84 [18468513.001]
  • [Cites] Science. 2000 Jan 7;287(5450):138-42 [10615049.001]
  • (PMID = 19926617.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK080703-01A1; United States / NIDDK NIH HHS / DK / R01 DK080703; United States / NIDDK NIH HHS / DK / DK073327-02; United States / NIDDK NIH HHS / DK / R21 DK073327-02; United States / NIDDK NIH HHS / DK / R21 DK073327; United States / NIDDK NIH HHS / DK / DK080703-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cholagogues and Choleretics; 0 / GPBAR1 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Reactive Oxygen Species; 0 / Receptors, G-Protein-Coupled; 516-50-7 / Taurodeoxycholic Acid; EC 1.6.- / NOX5 protein, human; EC 1.6.3.1 / NADPH Oxidase; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gq-G11
  • [Other-IDs] NLM/ NIHMS182037; NLM/ PMC3049934
  •  go-up   go-down


90. Keld R, Guo B, Downey P, Gulmann C, Ang YS, Sharrocks AD: The ERK MAP kinase-PEA3/ETV4-MMP-1 axis is operative in oesophageal adenocarcinoma. Mol Cancer; 2010 Dec 09;9:313
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ERK MAP kinase-PEA3/ETV4-MMP-1 axis is operative in oesophageal adenocarcinoma.
  • RESULTS: Here, we have studied the expression of the PEA3 subfamily members PEA3/ETV4 and ER81/ETV1 in oesophageal adenocarcinomas and determined their role in oesophageal adenocarcinoma cell function.
  • PEA3 plays an important role in controlling both the proliferation and invasive properties of OE33 oesophageal adenocarcinoma cells.
  • Enhanced ERK signaling is also more prevalent in late stage oesophageal adenocarcinomas.
  • CONCLUSIONS: This study shows that the ERK-PEA3-MMP-1 axis is upregulated in oesophageal adenocarcinoma cells and is a potentially important driver of the metastatic progression of oesophageal adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Oct 15;89(8):1670-6 [11042559.001]
  • [Cites] J Pathol. 1998 Jul;185(3):256-61 [9771478.001]
  • [Cites] Gut. 2001 Sep;49(3):330-4 [11511552.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Nov;2(11):827-37 [11715049.001]
  • [Cites] Ann Oncol. 2001 Oct;12(10):1407-10 [11762812.001]
  • [Cites] Neuron. 2002 Aug 29;35(5):877-92 [12372283.001]
  • [Cites] Ann Oncol. 2002 Oct;13(10):1568-75 [12377644.001]
  • [Cites] World J Gastroenterol. 2003 Feb;9(2):205-8 [12532432.001]
  • [Cites] Gene. 2003 Jan 16;303:11-34 [12559563.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Mar 1;17(5):655-64 [12641514.001]
  • [Cites] Int J Oncol. 2003 Aug;23(2):469-76 [12851697.001]
  • [Cites] J Pathol. 2003 Aug;200(5):568-76 [12898592.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2003 Apr;8(2):177-90 [14635793.001]
  • [Cites] Carcinogenesis. 2004 Mar;25(3):325-32 [14604892.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):20794-806 [14990565.001]
  • [Cites] Gut. 2004 Aug;53(8):1070-4 [15247170.001]
  • [Cites] Cancer Sci. 2004 Aug;95(8):626-33 [15298723.001]
  • [Cites] Ann Oncol. 1994 Sep;5(7):609-16 [7993836.001]
  • [Cites] Oncogene. 1996 Jan 18;12(2):221-7 [8570199.001]
  • [Cites] J Biol Chem. 1996 Sep 27;271(39):23907-13 [8798622.001]
  • [Cites] Oncogene. 1996 Sep 19;13(6):1323-33 [8808707.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jul 9;236(1):79-82 [9223430.001]
  • [Cites] Ann Intern Med. 2005 Aug 2;143(3):199-211 [16061918.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):12-30 [16378161.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4529-38 [16738319.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1766(1):79-87 [16546322.001]
  • [Cites] World J Gastroenterol. 2006 Dec 28;12(48):7859-63 [17203534.001]
  • [Cites] Eur J Surg Oncol. 2007 Apr;33(3):307-13 [17123775.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3279-90 [17496922.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 22;358(1):53-8 [17467662.001]
  • [Cites] Mol Cancer Res. 2007 May;5(5):413-21 [17475671.001]
  • [Cites] Mol Endocrinol. 2007 Aug;21(8):1835-46 [17505060.001]
  • [Cites] Genes Dev. 2007 Aug 1;21(15):1882-94 [17652178.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):595-9 [17671502.001]
  • [Cites] Dev Biol. 2009 Jan 1;325(1):106-21 [18977342.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2009 Jan;41(1):63-8 [19129951.001]
  • [Cites] Gastrointest Endosc. 2009 Apr;69(4):777-83 [19136106.001]
  • [Cites] Mol Cell Biol. 2009 Jun;29(11):3204-18 [19307308.001]
  • [Cites] Nucleic Acids Res. 2009 Dec;37(22):7368-80 [19789270.001]
  • [Cites] Oncogene. 1998 Jan 22;16(3):301-10 [9467955.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):276-82 [11161388.001]
  • (PMID = 21143918.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenovirus E1A Proteins; 0 / ETV4 protein, human; 0 / Proto-Oncogene Proteins; 0 / Transcription Factors; 0 / transcription factor PEA3; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.4.24.7 / Matrix Metalloproteinase 1
  • [Other-IDs] NLM/ PMC3009708
  •  go-up   go-down


91. Langer R, Ott K, Feith M, Lordick F, Specht K, Becker K, Hofler H: High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. J Surg Oncol; 2010 Oct 1;102(5):503-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients.
  • BACKGROUND: The aim of this study was to determine whether pretherapeutic protein expression levels of the excision repair cross-complementing (ERCC1) enzyme, thymidylate synthetase (TS), multidrug-resistance protein 1 (MRP-1) and P-glycoprotein (P-gp) are associated with tumour response to cisplatin and fluorouracil (5-FU)-based neoadjuvant chemotherapy in oesophageal adenocarcinomas.
  • METHODS: The expression levels of ERCC1, TS, MDR-1 and P-gp were determined immunohistochemically in pretherapeutic tumour biopsies from 40 oesophageal adenocarcinoma patients and were correlated with histopathological tumour regression and with patient survival.
  • CONCLUSIONS: The pattern of pretherapeutic expression of TS and MRP-1 is related to chemotherapy response in oesophageal adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Esophageal Neoplasms / drug therapy. Neoplasm Proteins / metabolism. P-Glycoprotein / metabolism. Thymidylate Synthase / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] J. Surg. Oncol. 2010;102:503-508. © 2010 Wiley-Liss, Inc.
  • (PMID = 20589706.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / P-Glycoprotein; EC 2.1.1.45 / Thymidylate Synthase; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


92. Bhandari P, Bateman AC, Mehta RL, Stacey BS, Johnson P, Cree IA, Di Nicolantonio F, Patel P: Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus. BMC Cancer; 2006;6:134
University of Turin Instituional Repository AperTO. Full Text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus.
  • The aim of our study was to test the hypothesis that higher levels of COX-2 expression are prognostically related to poor clinico-pathologic features in adenocarcinoma of the oesophagus.
  • METHODS: We reviewed the records of 100 consecutive patients undergoing resection for adenocarcinoma of the oesophagus to collect data on T-stage, N-stage, tumour recurrence and survival.
  • CONCLUSION: Higher levels of COX-2 expression are associated with poor clinico-pathologic features and poor survival in patients with oesophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cyclooxygenase 2 / metabolism. Esophageal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(8):1274-9 [10604722.001]
  • [Cites] Histopathology. 2005 Mar;46(3):280-6 [15720413.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1229-38 [10778945.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5767-72 [11059772.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Gastroenterology. 2002 Jun;122(7):1800-7 [12055587.001]
  • [Cites] J Biol Chem. 2002 Dec 27;277(52):50828-33 [12393872.001]
  • [Cites] Histopathology. 2003 May;42(5):457-65 [12713622.001]
  • [Cites] Dis Esophagus. 2004;17(2):136-40 [15230726.001]
  • [Cites] Cancer Res. 1989 Feb 15;49(4):1052-6 [2643460.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7384-8 [1380156.001]
  • [Cites] J Biol Chem. 1992 Dec 25;267(36):25934-8 [1464605.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1322-7 [8443812.001]
  • [Cites] J Biol Chem. 1993 Apr 25;268(12):9049-54 [8473346.001]
  • [Cites] Nature. 1994 Jan 20;367(6460):215-6 [8121485.001]
  • [Cites] Semin Oncol. 1994 Aug;21(4):403-10 [8042037.001]
  • [Cites] J Gastroenterol. 1994 Jul;29 Suppl 7:73-6 [7921158.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4566-9 [8840961.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1276-80 [9102213.001]
  • [Cites] Jpn J Cancer Res. 1997 Jun;88(6):600-4 [9263538.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):409-12 [9458081.001]
  • [Cites] Cell. 1998 May 29;93(5):705-16 [9630216.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2929-34 [9679948.001]
  • [Cites] Gastroenterology. 1998 Aug;115(2):297-306 [9679035.001]
  • [Cites] Am J Physiol. 1998 Jun;274(6 Pt 1):G1061-7 [9696706.001]
  • [Cites] Hepatology. 1999 Mar;29(3):688-96 [10051469.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):987-90 [10070951.001]
  • [Cites] Am J Surg. 2005 Jan;189(1):110-5 [15701502.001]
  • [Cites] Lab Invest. 1999 Dec;79(12):1469-77 [10616198.001]
  • (PMID = 16712734.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ PMC1481577
  •  go-up   go-down


93. Lagergren J, Jansson C, Viklund P: Chewing gum and risk of oesophageal adenocarcinoma: a new hypothesis tested in a population-based study. Eur J Cancer; 2006 Sep;42(14):2359-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chewing gum and risk of oesophageal adenocarcinoma: a new hypothesis tested in a population-based study.
  • The aim of this study was to test the hypothesis that chewing gum is associated with risk of oesophageal and cardia adenocarcinoma.
  • All patients were prospectively and uniformly documented and classified shortly after diagnosis.
  • In all, 189 and 262 patients with oesophageal and cardia adenocarcinoma, respectively, and 820 population-based control subjects were interviewed.
  • Regular users of chewing gum (P3 times/week for P6 months) were not at increased risk of oesophageal adenocarcinoma (OR 1.0, 95% CI 0.6-2.2), and no duration-response relation was observed (P = 0.38).
  • No association between regular gum chewing and cardia adenocarcinoma was found (OR 1.0, 95% CI 0.6-1.7), irrespective of duration of use (P = 0.56).
  • In conclusion, with regard to risk of oesophageal or cardia adenocarcinoma, gum chewing seems harmless.
  • [MeSH-major] Adenocarcinoma / etiology. Cardia. Chewing Gum / adverse effects. Esophageal Neoplasms / etiology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890425.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chewing Gum
  •  go-up   go-down


94. Savoy AD, Wallace MB: EUS in the management of the patient with dysplasia in Barrett's esophagus. J Clin Gastroenterol; 2005 Apr;39(4):263-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EUS in the management of the patient with dysplasia in Barrett's esophagus.
  • Barrett's esophagus is the most important risk factor in the development of adenocarcinoma of the esophagus.
  • Barrett's esophagus is generally regarded as the most significant complication of gastroesophageal reflux disease.
  • Adenocarcinoma occurs more frequently in the setting of high-grade dysplasia.
  • The prognosis of adenocarcinoma of the esophagus is strongly correlated with the stage of disease.
  • Esophagectomy has been the definitive treatment of limited stage adenocarcinoma of the esophagus.
  • Traditional evaluation of the patient with Barrett's esophagus with high-grade dysplasia includes esophago-gastro-duodenoscopy (EGD) with biopsy and computed tomography of the chest.
  • Endoscopic ultrasound (EUS) has gained popularity in the evaluation of the patient with Barrett's esophagus and high-grade dysplasia because it is the only imaging technique capable of delineating the separate histologic layers of the gastrointestinal tract.
  • This review of the literature summarizes the ability of EUS to evaluate patients with Barrett's esophagus and high-grade dysplasia.
  • [MeSH-major] Adenocarcinoma / ultrasonography. Barrett Esophagus / ultrasonography. Endosonography. Esophageal Neoplasms / ultrasonography. Precancerous Conditions / ultrasonography
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Humans. Reproducibility of Results

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15758616.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


95. Jones RJ, Hawkins RE, Eatock MM, Ferry DR, Eskens FA, Wilke H, Evans TR: A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemother Pharmacol; 2008 Mar;61(3):435-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma.
  • PURPOSE: Combination chemotherapy regimens can improve survival in patients with advanced gastric and oesophageal adenocarcinoma.
  • PATIENTS AND METHODS: In this single arm, phase II study of DHA-paclitaxel, eligible patients with previously untreated, inoperable locally advanced or metastatic adenocarcinoma of the oesophagus, oesophago-gastric junction or stomach were treated with DHA-paclitaxel (1,100 mg/m(2)) administered by 2-h intravenous infusion every 21 days.
  • CONCLUSIONS: DHA-paclitaxel has modest activity in patients with oesophago-gastric cancer and with haematological toxicity that is comparable to paclitaxel and docetaxel.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Esophageal Neoplasms / drug therapy. Paclitaxel / analogs & derivatives. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440725.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / docosahexaenoyl-paclitaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


96. Sampliner RE: Managing Barrett's esophagus: what is new in 2005? Dis Esophagus; 2005;18(1):17-20
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Managing Barrett's esophagus: what is new in 2005?
  • The new developments in the management of Barrett's esophagus in 2005 result in refinements of decision making.
  • Endoscopic mucosal resection is being more widely applied resulting in more accurate staging of patients with early adenocarcinoma of the esophagus and helping to define patients amenable to endoscopic therapy.
  • The impact of medical therapy of GERD and anti-reflux surgery on the development of esophageal adenocarcinoma is disappointing.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15773836.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


97. Brabender J, Marjoram P, Lord RV, Metzger R, Salonga D, Vallböhmer D, Schäfer H, Danenberg KD, Danenberg PV, Selaru FM, Baldus SE, Hölscher AH, Meltzer SJ, Schneider PM: The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma. Cancer Epidemiol Biomarkers Prev; 2005 Sep;14(9):2113-7
The Lens. Cited by Patents in